Updated on 2026/03/09

All information, except for affiliations, is reprinted from the information registered on researchmap.

写真a

 
Ryu Kobayashi
 
Organization
Yokohama City University Hospital Assistant Professor
Title
Assistant Professor
Homepage
http://www.yokohama-medicine.org/
Profile

レニン・アンジオテンシン系に着目した慢性腎臓病，高血圧，心血管疾患の病態解析とアンジオテンシン受容体結合因子ATRAPに着目した新規治療法の探索．レニン・アンジオテンシン系の視点から慢性腎臓病に対する特異的治療，病態の解明．また，血圧変動性や家庭血圧に着目した血圧管理の目標，内服タイミング，降圧薬の選択．

血液透析、腹膜透析、在宅血液透析、腎移植を個別性に応じて提供し“包括的腎代替療法” を実践.

External link

Degree

  • 博士（医学） ( 横浜市立大学 )

Research Interests

  • レニン・アンジオテンシン系

  • renal replacement therapy

  • 慢性腎臓病

Research Areas

  • Life Science / Metabolism and endocrinology

  • Life Science / Nephrology

Education

  • Yokohama City University   Graduate   Graduate School of Medicine

    2013.4 - 2017.3

    　 More details

  • 横浜市立大学医学部   医学科

    2003.4 - 2009.3

    　 More details

Research History

  • Yokohama City University

    2025.4

    　 More details

  • Yokohama City University   Hospital Nephrology/Hypertension   Assistant Professor

    2022.4 - 2025.4

    　 More details

  • 日本赤十字社医療センター   腎臓内科

    2020.4 - 2022.3

    　 More details

  • Yokohama City University   Assistant Professor

    2017.4 - 2020.3

    　 More details

  • Yokohama City University   Nephrology/Hypertension, Hospital

    2016.12 - 2017.3

    　 More details

  • Yokohama City University   Graduate School of Medicine, Graduate

    2013.4 - 2017.3

    　 More details

  • 茅ヶ崎市立病院 腎臓内科 医員

    2011.4 - 2013.3

    　 More details

  • Yokohama City University   Hospital

    2009.4 - 2011.3

    　 More details

▼display all

Professional Memberships

▼display all

Papers

  • Effects of proximal tubule-specific ATRAP enhancement on hypertension in a remnant kidney chronic kidney disease model of mice. International journal

    Naohito Okami, Hiromichi Wakui, Shohei Tanaka, Ryu Kobayashi, Shunichiro Tsukamoto, Shinya Taguchi, Ryutaro Morita, Eisuke Kubo, Akio Yamashita, Kengo Azushima, Kouichi Tamura

    Scientific reports   15 ( 1 )   27391 - 27391   2025.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Chronic kidney disease (CKD) frequently accompanies hypertension, exacerbating CKD progression in a vicious cycle. Angiotensin II type 1 receptor-associated protein (ATRAP) promotes AT1 receptor internalization to inhibit hyperactivation of its downstream signaling. We previously reported that the downregulation of renal ATRAP expression had a critical role in the development of hypertension in a remnant kidney CKD model, through activation of epithelial sodium channel (ENaC) pathway. Although the distal-tubule was highlighted in CKD-related hypertension, the proximal tubule's role remained unclear. We generated proximal tubule-specific ATRAP transgenic (PT-ATRAP Tg) mice under the control of the Npt2 promoter and compared the effects of 5/6 nephrectomy (Nx) on blood pressure (BP) with those in littermate control (LC) wild-type mice. Immunohistochemical and laser microdissection analyses revealed that the proximal tubule-specific overexpression of ATRAP in PT-ATRAP Tg mice resulted in approximately 15-fold increase in ATRAP mRNA expression in the proximal tubules compared to LC mice. There were no significant differences in body weight, systolic BP, heart rate, and renal function between PT-ATRAP Tg and LC mice at baseline before surgery. Furthermore, twelve weeks after surgery, both PT-ATRAP Tg and LC mice that underwent 5/6 nephrectomy showed a similar increase in systolic BP compared to sham-operated mice, with no significant differences. Additionally, 5/6 Nx elevated renal ENaCα expression similarly in both groups. In conclusion, increased ATRAP expression in the proximal tubules does not affect hypertension in the remnant kidney CKD model, suggesting a pathological significance of distal tubules in this disease model.

    DOI： 10.1038/s41598-025-12168-3

    PubMed

    researchmap

  • IgA vasculitis with nephritis accompanied by pulmonary tuberculosis: a case report.

    Eriko Abe, Ryu Kobayashi, Rio Matsuoka, Tomohiko Kanaoka, Shoji Yamanaka, Satoshi Fujii, Junki Koike, Takashi Oda, Hiromichi Wakui, Kouichi Tamura

    CEN case reports   14 ( 3 )   421 - 427   2025.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A 69-year-old Japanese man developed abdominal pain, purpura, proteinuria, and hematuria while receiving treatment for pulmonary tuberculosis. A skin biopsy revealed IgA-positive leukocytoclastic vasculitis, and a renal biopsy showed IgA-positive mesangial proliferative glomerulonephritis with crescent formation. Based on these findings, we diagnosed IgA vasculitis with nephritis (IgAVN) and initiated treatment. The patient's abdominal symptoms improved following factor XIII supplementation and corticosteroids. Corticosteroids were administered, and after 5 months, the proteinuria was in complete remission. Although IgAVN often follows a prior infection, it is rarely complicated by tuberculosis. In this case, staining for galactose-deficient IgA1, which is specifically positive in IgA nephropathy and IgAVN, was positive. Nephritis-associated plasmin receptor staining was also positive, suggesting some involvement of infectious glomerulonephritis. Therefore, the patient was considered to have IgAVN associated with pulmonary tuberculosis. In adult-onset cases, IgAVN is often severe. This patient was presented with adult-onset nephrosis and International Study of Kidney Disease in Children grade IIIb IgAVN, suggesting a poor prognosis. Therefore, we immediately initiated treatment with corticosteroids, factor XIII supplementation, a renin-aldosterone-system inhibitor, and a sodium-glucose cotransporter 2 inhibitor. The patient recovered uneventfully with no worsening of tuberculosis.

    DOI： 10.1007/s13730-025-00966-7

    PubMed

    researchmap

  • Keratinocyte-specific angiotensin II receptor-associated protein deficiency exacerbates angiotensin II-dependent hypertension via activation of the skin renin-angiotensin system. International journal

    Shinya Taguchi, Kengo Azushima, Kento Kitada, Norihiko Morisawa, Satoshi Kidoguchi, Ryutaro Morita, Kazuya Nakagawa, Atsushi Ishibe, Itaru Endo, Keisuke Kazama, Yasushi Rino, Aya Saito, Sho Kinguchi, Ryu Kobayashi, Taiji Matsusaka, Akio Yamashita, Hiromichi Wakui, Akira Nishiyama, Kouichi Tamura

    Nature communications   16 ( 1 )   4789 - 4789   2025.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The skin has recently been highlighted as a new player regulating blood pressure (BP). Here we show the role of skin renin-angiotensin system (RAS) in hypertension. In human subjects, skin expression of angiotensin II (Ang II) type 1 receptor (AT1R)-associated protein (ATRAP), which inhibits pathological AT1R signaling, is inversely correlated with systolic BP. Keratinocyte-specific ATRAP knockout male mice (KO) exhibit exacerbated Ang II-induced hypertension and skin-specific increases in angiotensinogen and Ang II levels. In keratinocyte-specific ATRAP and AT1R knockout male mice, Ang II-induced skin angiotensinogen excess and exaggerated hypertension seen in KO are eliminated. Although body fluid volume is comparable between the genotypes, the urine volume per water intake in Ang II-infused KO is increased, suggesting decreased extra-renal water loss, which is supported by decreased skin blood flow and transepidermal water loss in KO. Body temperature elevation-induced skin vasodilation eliminates these differences, including exaggerated hypertension, indicating the contribution of skin RAS-mediated vasoconstriction to BP elevation. Skin RAS may become a potential strategy for therapeutic interventions in hypertension.

    DOI： 10.1038/s41467-025-60041-8

    PubMed

    researchmap

  • Proteomic serum profiles before and after lipoprotein apheresis in patients with peripheral artery disease with ulceration. International journal

    Kohei Ishiga, Tatsuki Uehara, Hiromichi Wakui, Kengo Azushima, Eiko Ueda, Daisuke Kanai, Mari Sotozawa, Ryu Kobayashi, Sho Kinguchi, Tomohiko Kanaoka, Tatsuya Haze, Yoshiyuki Toya, Kouichi Tamura

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy   2024.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: The efficacy of lipoprotein apheresis (LA) in peripheral arterial disease (PAD) has been primarily attributed to its anti-atherosclerotic effects through the adsorption of lipoproteins. However, the other potential effects of LA remain unknown. We evaluated changes in serum profiles before and after LA using a comprehensive analysis to explore the underlying mechanism. METHODS: Ten patients with leg ulcers were included from the LETS-PAD study, in which patients with lipoprotein-controlled PAD underwent LA. Serum samples collected at baseline and 1 month after LA were analyzed for proteomic changes. RESULTS: Six patients exhibited ulcer epithelialization and skin perfusion pressure improvement. Proteomic analysis identified 2033 proteins. Fifty-five proteins showed significant differences. B-cell lymphoma protein-2 associated X (BAX) and C-X-C motif chemokine 10 (CXCL10) were downregulated. CONCLUSION: Serum BAX and CXCL10 levels significantly decreased after LA, which may be involved in the ulcer epithelialization mechanism of LA, which potentially acts through angiogenesis promotion.

    DOI： 10.1111/1744-9987.14247

    PubMed

    researchmap

  • Clinical Course and Factors Correlated with Severe Morbidity and Mortality in Patients with Coronavirus Disease 2019 Undergoing Maintenance Dialysis in Kanagawa, Japan.

    Kohei Ishiga, Hiromichi Wakui, Kengo Azushima, Tomohiko Kanaoka, Daisuke Kanai, Ryu Kobayashi, Sho Kinguchi, Naohito Okami, Tatsuya Haze, Takehisa Iwano, Masashi Sakai, Kohji Ohki, Jin Oshikawa, Toshiharu Kokuho, Masaaki Hanaoka, Hiroshi Mitsuhashi, Yukiko Yamada, Machiko Yabana, Yoshiyuki Toya, Kouichi Tamura

    Internal medicine (Tokyo, Japan)   63 ( 23 )   3157 - 3163   2024.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Objective Patients undergoing maintenance dialysis are at a higher risk of morbidity and mortality due to severe coronavirus disease 2019 (COVID-19) than the general population. However, longitudinal data regarding this subpopulation of patients are lacking. We therefore examined the prognosis of patients with COVID-19 undergoing maintenance dialysis between 2020 and 2023. In addition, we explored the factors correlated with COVID-19 severity, focusing on the transition thereof throughout the observational period. Methods The primary outcome was the progression to severe or fatal COVID-19. We evaluated the correlation between the primary outcome and baseline demographic and clinical characteristics of patients. Patients undergoing maintenance dialysis who were hospitalized for mild-to-moderate COVID-19 between February 2020 and April 2023 were enrolled at four institutions in Kanagawa, Japan. Results Of the 173 patients, 7 (4.0%) developed severe COVID-19, and 12 (6.9%) died. The severe/death cohort was significantly older, with a higher percentage of unvaccinated patients than the non-severe cohort (58.2% and 25.0%, respectively; p=0.016). Thymus and activation-regulated chemokine levels on admission were lower in the severe/death cohort than in the non-severe cohort, albeit not to a statistically significant degree (148±84 mg/dL and 342±657 pg/mL, respectively; p=0.082). A multivariate logistic regression analysis revealed that the odds ratio for severe morbidity or death was 0.23 (95% confidence interval: 0.07-0.75) for vaccinated patients. Conclusion In patients undergoing maintenance dialysis, the severity rate of COVID-19 is approximately 10%. Vaccination was correlated with a reduced risk of severe COVID-19.

    DOI： 10.2169/internalmedicine.4199-24

    PubMed

    researchmap

  • Impact of compliance with salt management guidelines before dialysis introduction on peritoneal dialysis technique survival: The importance of pre-dialysis care and education. International journal

    Ryu Kobayashi, Satoshi Kinugasa, Daisuke Kamano, Rena Sumura, Hirotoshi Kakiwaki, Tatsuya Haze, Keisuke Ono, Mai Yanagi, Kouichi Tamura, Yoshitaka Ishibashi

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy   28 ( 6 )   830 - 838   2024.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Peritoneal dialysis (PD) is a mode of therapy in which the patients themselves actively participate in the care of their own disease. We examined a possible association of salt reduction before starting dialysis with PD technique survival. METHODS: This retrospective cohort study included 42 patients who started PD between April 2014 and March 2018. Participants were allocated to two groups based on their estimated daily salt intake before the initiation of dialysis: patients with an estimated daily salt intake <6 g/day were allocated to the appropriate salt intake group (AS group), while the rest were assigned to the high salt intake group (HS group). RESULTS: During a median follow-up of 47 months, PD technique survival, defined by death or transition to hemodialysis, was significantly lower in the HS group compared to the AS group. CONCLUSION: Successful salt reduction before dialysis introduction is associated with better PD technique survival.

    DOI： 10.1111/1744-9987.14167

    PubMed

    researchmap

  • ロサルタンの漸減・中止に伴ってHb値が上昇し,再投与後低下した血液透析患者の1例

    矢花 眞知子, 涌井 広道, 古田 里華, 渡邊 祐樹, 石賀 浩平, 中野 雅友樹, 小林 竜, 小豆島 健護, 金岡 知彦, 池谷 裕子, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   57 ( Suppl.1 )   783 - 783   2024.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • ロサルタンの漸減・中止に伴ってHb値が上昇し,再投与後低下した血液透析患者の1例

    矢花 眞知子, 涌井 広道, 古田 里華, 渡邊 祐樹, 石賀 浩平, 中野 雅友樹, 小林 竜, 小豆島 健護, 金岡 知彦, 池谷 裕子, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   57 ( Suppl.1 )   783 - 783   2024.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • Correction to: Two acute kidney injury episodes after ICI therapy: a case report.

    Kohei Ishiga, Ryu Kobayashi, Tomohiko Kanaoka, Jotaro Harada, Ikuma Kato, Satoshi Fujii, Hiromichi Wakui, Yoshiyuki Toya, Kouichi Tamura

    CEN case reports   13 ( 5 )   416 - 418   2024.4

    　More details

  • Lipoprotein Apheresis Alleviates Treatment-Resistant Peripheral Artery Disease Despite the Normal Range of Atherogenic Lipoproteins: The LETS-PAD Study.

    Eiko Ueda, Yoshiyuki Toya, Hiromichi Wakui, Kohei Ishiga, Yuki Kawai, Ryu Kobayashi, Sho Kinguchi, Tomohiko Kanaoka, Yusuke Saigusa, Taro Mikami, Yuichiro Yabuki, Motohiko Goda, Daisuke Machida, Takayuki Fujita, Kotaro Haruhara, Teruyasu Sugano, Kengo Azushima, Kouichi Tamura

    Journal of atherosclerosis and thrombosis   31 ( 10 )   1370 - 1385   2024.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    AIM: Peripheral artery disease (PAD) severely impairs patient prognosis and quality of life (QOL). Although lipoprotein apheresis (LA) has been applied to patients with PAD and elevated serum atherogenic lipoproteins, we hypothesized that LA can be effective for treating PAD even in patients with controlled serum lipoproteins through pleiotropic anti-atherosclerotic effects beyond lipoprotein removal. This study aimed to evaluate the efficacy of LA in patients with treatment-resistant PAD and controlled serum lipoproteins focusing on QOL. METHODS: In a single-arm prospective study, 30 patients with refractory PAD who had controlled serum lipoproteins underwent sequential LA sessions using dextran sulfate adsorption columns, aiming to complete 10 sessions. The ankle-brachial pressure index (ABI) and vascular QOL (VascuQOL) score were evaluated as the primary outcomes. Secondary outcomes included reactive hyperemia index (RHI) and biological antioxidant potential (BAP) as an endothelial function test and serum antioxidative-capacity evaluation, respectively. RESULTS: ABI significantly increased after LA sessions (pre-treatment 0.60±0.09 vs. post-treatment 0.65±0.13, p=0.023). Total VascuQOL score (3.7±1.1 vs 4.6±1.1, p＜0.001) and RHI (1.70±0.74 vs 2.34±1.76, p=0.023) significantly improved after the LA sessions. BAP tended to increase after the LA sessions, and the change reached statistical significance 3 months after treatment. CONCLUSION: ABI and QOL improved after a series of LA sessions in conventional treatment-resistant PAD patients with controlled serum lipoprotein levels. Increased antioxidative capacity and ameliorated endothelial function were observed after the LA treatment.

    DOI： 10.5551/jat.64639

    PubMed

    researchmap

  • Two acute kidney injury episodes after ICI therapy: a case report.

    Kohei Ishiga, Ryu Kobayashi, Tomohiko Kanaoka, Jotaro Harada, Ikuma Kato, Satoshi Fujii, Hiromichi Wakui, Yoshiyuki Toya, Kouichi Tamura

    CEN case reports   13 ( 5 )   408 - 415   2024.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A 74-year-old Japanese male with lung squamous cell carcinoma received his first dose of immune checkpoint inhibitors (ICIs): ipilimumab and nivolumab. He developed acute kidney injury (AKI) and was admitted to our department. We diagnosed kidney immune-related adverse effects (irAE), and a kidney biopsy revealed acute tubulointerstitial nephritis. We started oral prednisolone (PSL) and his AKI immediately improved. The patient maintained stable findings after PSL was tapered off. However, seven months after the ICI administration, he developed rapid progressive glomerular nephritis and was admitted to our department again. The second kidney biopsy showed findings consistent with anti-glomerular basement membrane glomerulonephritis. Although the patient was treated with pulse methylprednisolone followed by oral PSL and plasma exchange, he became dependent on maintenance hemodialysis. To our knowledge, no case report has described two different types of biopsy-proven nephritis. In cases of suspected relapsing kidney irAEs, both a relapse of previous nephritis and the development of another type of nephritis should be considered.

    DOI： 10.1007/s13730-024-00855-5

    PubMed

    researchmap

  • Angiotensin II type 1 receptor-associated protein deletion combined with angiotensin II stimulation accelerates the development of diabetic kidney disease in mice on a C57BL/6 strain. International journal

    Shinya Taguchi, Kengo Azushima, Takahiro Yamaji, Toru Suzuki, Eriko Abe, Shohei Tanaka, Keigo Hirota, Shunichiro Tsukamoto, Ryutaro Morita, Ryu Kobayashi, Sho Kinguchi, Akio Yamashita, Hiromichi Wakui, Kouichi Tamura

    Hypertension research : official journal of the Japanese Society of Hypertension   47 ( 1 )   55 - 66   2023.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The progress in the research field of diabetic kidney disease (DKD) has been disturbed by the lack of reliable animal models. Angiotensin II (Ang II) type 1 receptor (AT1R)-associated protein (ATRAP) promotes internalization of AT1R and selectively inhibits pathological AT1R signaling. In this study, we investigated whether overactivation of the renin-angiotensin system (RAS) through a combination of ATRAP deletion with Ang II stimulation developed a progressive DKD model in C57BL/6 mice, which are resistant to the development of kidney injury. Eight-week-old male systemic ATRAP-knockout mice on the C57BL/6 strain (KO) and their littermate wild-type mice (Ctrl) were divided into five groups: 1) Ctrl, 2) Ctrl-streptozotocin (STZ), 3) KO-STZ, 4) Ctrl-STZ-Ang II, and 5) KO-STZ-Ang II. Ang II was administered for 6 weeks from 4 weeks after STZ administration. At 10 weeks after STZ administration, mice were euthanized to evaluate kidney injuries. Neither ATRAP deletion alone nor Ang II stimulation alone developed a progressive DKD model in STZ-induced diabetic C57BL/6 mice. However, a combination of ATRAP deletion with Ang II stimulation accelerated the development of DKD as manifested by overt albuminuria, glomerular hypertrophy, podocyte loss, mesangial expansion, kidney interstitial fibrosis and functional insufficiency, concomitant with increased angiotensinogen and AT1R expression in the kidneys. In STZ-induced diabetic C57BL/6 mice that are resistant to the development of kidney injury, the combination of ATRAP deletion and Ang II stimulation accelerates the development of DKD, which may be associated with intrarenal RAS overactivation.

    DOI： 10.1038/s41440-023-01496-4

    PubMed

    researchmap

  • 腎障害抵抗性C57BL/6マウスにおける新規糖尿病性腎臓病モデル作製の試み

    小豆島 健護, 田口 慎也, 森田 隆太郎, 小林 竜, 金口 翔, 涌井 広道, 田村 功一

    日本高血圧学会総会プログラム・抄録集   45回   275 - 275   2023.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 受容体結合蛋白ATRAPが腎尿細管機能制御と腎組織変化に及ぼす影響についての検討

    大用 凌太郎, 塚本 俊一郎, 大上 尚仁, 小林 竜, 金口 翔, 小豆島 健護, 金岡 知彦, 涌井 広道, 田村 功一

    日本高血圧学会総会プログラム・抄録集   45回   273 - 273   2023.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 正脂血症を呈する従来治療抵抗性末梢動脈疾患に対して、LDLアフェレシス療法はABIとQOLを改善させる(LETS-PAD study)

    植田 瑛子, 戸谷 義幸, 涌井 広道, 石賀 浩平, 上原 立己, 小林 竜, 金口 翔, 小豆島 健護, 金岡 知彦, 田村 功一

    日本高血圧学会総会プログラム・抄録集   45回   238 - 238   2023.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン受容体結合蛋白ATRAPの生体リズム調節機序を介した病態生理学的意義についての検討

    笠原 信太朗, 森田 隆太郎, 大上 尚仁, 小林 竜, 金口 翔, 小豆島 健護, 金岡 知彦, 涌井 広道, 田村 功一

    日本高血圧学会総会プログラム・抄録集   45回   277 - 277   2023.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 高蛋白食が腎臓に与える影響についての5/6腎摘CKDモデルマウスを用いての検討

    田中 翔平, 涌井 広道, 大上 尚仁, 浦手 進吾, 小林 竜, 小豆島 健護, 田村 功一

    日本高血圧学会総会プログラム・抄録集   45回   375 - 375   2023.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 腎尿細管RAS(renin-angiotensin system)の過剰活性化は尿細管M2マクロファージ発現を低下させ、糖尿病性糸球体障害を惹起する

    鈴木 徹, 春原 浩太郎, 涌井 広道, 小豆島 健護, 小林 竜, 金口 翔, 坪井 伸夫, 横尾 隆, 田村 功一

    日本高血圧学会総会プログラム・抄録集   45回   213 - 213   2023.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 免疫チェックポイント阻害薬投与後に急性尿細管間質性腎炎および抗GBM抗体型糸球体腎炎を呈した1例

    石賀 浩平, 小林 竜, 金岡 知彦, 藤井 誠志, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   65 ( 6-E )   592 - 592   2023.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 高度腎機能障害高血圧患者に対するサクビトリルバルサルタンへの切り替え投与が診察室外血圧に与える影響についての検討

    石賀 浩平, 金口 翔, 小林 竜, 小豆島 健護, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   45回   386 - 386   2023.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • High plasma aldosterone concentration is associated with worse 24-h ambulatory blood pressure profile in patients with primary aldosteronism. International journal

    Ryutaro Morita, Kengo Azushima, Sumire Sunohara, Tatsuya Haze, Ryu Kobayashi, Sho Kinguchi, Tomohiko Kanaoka, Kazuo Kobayashi, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura

    Hypertension research : official journal of the Japanese Society of Hypertension   46 ( 8 )   1995 - 2004   2023.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Patients with primary aldosteronism (PA) have a higher risk of cardiovascular disease (CVD) than essential hypertension due to underlying hyperaldosteronism. However, the association between high plasma aldosterone concentrations (PACs) and diurnal blood pressure (BP) variation has not been fully elucidated. Because abnormal ambulatory blood pressure monitoring (ABPM) profiles are associated with increased CVD risk, we investigated the association between PACs and the ABPM profile in 36 patients with PA diagnosed by confirmatory tests who underwent adrenal venous sampling (AVS). The clinical parameters were measured during hospitalization for AVS. The dietary salt intake of hospitalized patients was controlled at 6 g/day. During AVS, blood samples were collected from the inferior vena cava before and 1 h after adrenocorticotropic hormone (ACTH) stimulation to measure the PACs. The post-stimulation PAC had a significant negative correlation with nocturnal BP dipping rates (R = -0.387, p = 0.020), whereas pre-stimulation PAC did not (R = -0.217, p = 0.204). The nocturnal BP dipping rates were significantly lower in the high PAC group (PAC higher than the median) than low PAC group (PAC lower than the median) (p = 0.009). Multiple regression analysis revealed that high PAC was an independent factor contributing to low nocturnal BP dipping rates (β = -0.316, p = 0.038). In conclusion, in patients with PA, hyperaldosteronism is associated with nocturnal hypertension, which is an important risk factor for CVD. Additionally, ACTH stimulation may improve the sensitivity of PACs as a clinical indicator of nocturnal hypertension.

    DOI： 10.1038/s41440-023-01325-8

    PubMed

    researchmap

  • 維持透析COVID-19患者における重症化予測因子の検討

    石賀 浩平, 涌井 広道, 金岡 知彦, 小林 竜, 酒井 政司, 押川 仁, 澁谷 研, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   56 ( Suppl.1 )   509 - 509   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 高トリグリセリド血症に対してペマフィブラートを使用した血液透析患者の一例

    金岡 知彦, 石賀 浩平, 小林 竜, 富樫 優, 涌井 広道, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   56 ( Suppl.1 )   531 - 531   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 腫瘍随伴症候群による高Ca血症に対し血液透析を施行した3例

    金口 翔, 加藤 実玖, 浦手 進吾, 小豆島 健護, 小林 竜, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   56 ( Suppl.1 )   455 - 455   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 無除水透析期間13年4ヵ月,あるいは10年11ヵ月を経た後,尿量減少のため除水を開始した血液透析患者の2例

    矢花 眞知子, 涌井 広道, 石賀 浩平, 浦手 進吾, 植田 瑛子, 小林 竜, 小豆島 健護, 金岡 知彦, 坂 早苗, 池谷 裕子, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   56 ( Suppl.1 )   694 - 694   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 5/6腎摘CKDモデルマウスにおいて,高蛋白食負荷が糸球体障害と尿細管障害へ及ぼす影響について

    田中 翔平, 涌井 広道, 大上 尚仁, 浦手 進吾, 小林 竜, 小豆島 健護, 田村 功一

    日本腎臓学会誌   65 ( 3 )   293 - 293   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Effects of a High-Protein Diet on Kidney Injury under Conditions of Non-CKD or CKD in Mice. International journal

    Shohei Tanaka, Hiromichi Wakui, Kengo Azushima, Shunichiro Tsukamoto, Takahiro Yamaji, Shingo Urate, Toru Suzuki, Eriko Abe, Shinya Taguchi, Takayuki Yamada, Ryu Kobayashi, Tomohiko Kanaoka, Daisuke Kamimura, Sho Kinguchi, Masahito Takiguchi, Kengo Funakoshi, Akio Yamashita, Tomoaki Ishigami, Kouichi Tamura

    International journal of molecular sciences   24 ( 9 )   2023.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Considering the prevalence of obesity and global aging, the consumption of a high-protein diet (HPD) may be advantageous. However, an HPD aggravates kidney dysfunction in patients with chronic kidney disease (CKD). Moreover, the effects of an HPD on kidney function in healthy individuals are controversial. In this study, we employed a remnant kidney mouse model as a CKD model and aimed to evaluate the effects of an HPD on kidney injury under conditions of non-CKD and CKD. Mice were divided into four groups: a sham surgery (sham) + normal diet (ND) group, a sham + HPD group, a 5/6 nephrectomy (Nx) + ND group and a 5/6 Nx + HPD group. Blood pressure, kidney function and kidney tissue injury were compared after 12 weeks of diet loading among the four groups. The 5/6 Nx groups displayed blood pressure elevation, kidney function decline, glomerular injury and tubular injury compared with the sham groups. Furthermore, an HPD exacerbated glomerular injury only in the 5/6 Nx group; however, an HPD did not cause kidney injury in the sham group. Clinical application of these results suggests that patients with CKD should follow a protein-restricted diet to prevent the exacerbation of kidney injury, while healthy individuals can maintain an HPD without worrying about the adverse effects.

    DOI： 10.3390/ijms24097778

    PubMed

    researchmap

  • 5/6腎摘CKDモデルマウスを用いた、非CKDおよびCKDの条件下での腎障害に対する高蛋白食の影響について

    田中 翔平, 涌井 広道, 大上 尚仁, 浦手 進吾, 小林 竜, 小豆島 健護, 田村 功一

    日本臨床分子医学会学術総会プログラム・抄録集   58回   55 - 55   2023.4

    　More details

    Language：Japanese   Publisher：日本臨床分子医学会  

    researchmap

  • Development of prediction models for domestic chores resumption among mild stroke patients three months after discharge from specialized rehabilitation wards: A multi-center prospective cohort study. International journal

    Ryu Kobayashi, Norikazu Kobayashi

    Topics in stroke rehabilitation   30 ( 3 )   235 - 245   2023.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Whether stroke patients resume domestic chores is one of the major issues associated with their quality of life. Prediction models for domestic chores resumption among stroke survivors can be useful for setting goals and planning rehabilitation. OBJECTIVES: To develop prediction models for individual domestic chores resumption among mild stroke patients three months after discharge from specialized rehabilitation wards. METHODS: Ninety-one stroke patients admitted to specialized rehabilitation wardswere included in the analyses. We assessed the prestroke and three months post-discharge frequencies of six domestic chore items of the Frenchay Activities Index. Demographics and candidate predictors such as paralysis severity, cognitive function, walking speed, and self-efficacy were collected at discharge. Binary logistic regression analyses were performed to build prediction models for individual domestic chores resumption after stroke. RESULTS: The preparing meals model included walking speed (OR = 1.05) and cognitive function (OR = 1.29) as predictors; washing up model, walking speed (OR = 1.04); washing clothes model, walking speed (OR = 1.06), and number of family members living together (OR = 0.42); light housework model, walking speed (OR = 1.06); heavy housework model, walking speed (OR = 1.03), cognitive function (OR = 1.38), and self-efficacy (OR = 1.91); and local shopping model, walking speed (OR = 1.05), age (OR = 0.94), and number of family members living together (OR = 0.61). CONCLUSIONS: Our models may be useful in clinical practice to streamline the setting of goals and development of therapeutic strategies for individual domestic chores resumption among mild stroke patients.

    DOI： 10.1080/10749357.2022.2026279

    PubMed

    researchmap

  • 慢性透析中のCOVID-19患者における重症化に関連した患者背景・因子についての検討

    石賀 浩平, 小林 竜, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本内科学会雑誌   112 ( 臨増 )   182 - 182   2023.2

    　More details

    Language：Japanese   Publisher：(一社)日本内科学会  

    researchmap

  • Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. International journal

    Shunichiro Tsukamoto, Ryutaro Morita, Takayuki Yamada, Shingo Urate, Kengo Azushima, Kazushi Uneda, Ryu Kobayashi, Tomohiko Kanaoka, Hiromichi Wakui, Kouichi Tamura

    Diabetes research and clinical practice   194   110161 - 110161   2022.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    AIMS: Both sodium-glucose cotransporter-2 (SGLT-2) inhibitors and mineralocorticoid receptor antagonists (MRAs) have been shown to reduce cardiovascular (CV) event in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). However, little evidence pertains to the benefits of their combined use. METHODS: We systematically searched the PubMed, MEDLINE, EMBASE, and Cochrane Library databases through July 2022. We selected randomized controlled trials comparing SGLT-2 inhibitors, MRAs, or SGLT-2 inhibitor + MRA combination therapy, with placebo in patients with T2D and CKD. We performed a network meta-analysis to indirectly compare the treatments. The primary outcome was a composite of CV events. RESULTS: Eight studies were selected with 36,186 patients. The primary outcome was significantly improved in the combination therapy group compared with the other groups (RR [95% CI]; vs SGLT-2 inhibitors, 0.76 [0.60; 0.96]; vs MRAs, 0.66 [0.53; 0.82]; vs placebo, 0.58 [0.47; 0.73]). Additionally, the combination therapy was associated with a considerable reduction in the risk of hyperkalemia (RR vs MRA, 0.43 [0.23; 0.79]). CONCLUSION: Combination of SGLT-2 inhibitors and MRAs potentially reduced CV events compared with SGLT-2 inhibitors or MRAs alone. This combination may be a candidate treatment strategy for patients with T2D and CKD.

    DOI： 10.1016/j.diabres.2022.110161

    PubMed

    researchmap

  • 経皮的腎生検困難な症例に対しガリウムシンチグラフィによりIgG4関連間質性腎炎と診断し治療開始できた一例

    福岡 昭宏, 小豆島 健護, 加藤 実玖, 吉村 汐莉, 浦手 進吾, 石賀 浩平, 金口 翔, 小林 竜, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   64 ( 6-E )   584 - 584   2022.10

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization. International journal

    Kotaro Haruhara, Toru Suzuki, Hiromichi Wakui, Kengo Azushima, Daisuke Kurotaki, Wataru Kawase, Kazushi Uneda, Ryu Kobayashi, Kohji Ohki, Sho Kinguchi, Takahiro Yamaji, Ikuma Kato, Kenichi Ohashi, Akio Yamashita, Tomohiko Tamura, Nobuo Tsuboi, Takashi Yokoo, Kouichi Tamura

    Kidney international   101 ( 5 )   912 - 928   2022.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Although activation of the renin-angiotensin system and of its glomerular components is implicated in the pathogenesis of diabetic nephropathy, the functional roles of the tubular renin-angiotensin system with AT1 receptor signaling in diabetic nephropathy are unclear. Tissue hyperactivity of the renin-angiotensin system is inhibited by the angiotensin II type 1 receptor-associated protein ATRAP, which negatively regulates receptor signaling. The highest expression of endogenous ATRAP occurs in the kidney, where it is mainly expressed by tubules but rarely in glomeruli. Here, we found that hyperactivation of angiotensin II type 1 receptor signaling in kidney tubules exacerbated diabetic glomerular injury in a mouse model of streptozotocin-induced diabetic nephropathy. These phenomena were accompanied by decreased expression of CD206, a marker of alternatively activated and tissue-reparative M2 macrophages, in the kidney tubulointerstitium. Additionally, adoptive transfer of M2- polarized macrophages into diabetic ATRAP-knockout mice ameliorated the glomerular injury. As a possible mechanism, the glomerular mRNA levels of tumor necrosis factor-α and oxidative stress components were increased in diabetic knockout mice compared to non-diabetic knockout mice, but these increases were ameliorated by adoptive transfer. Furthermore, proximal tubule-specific ATRAP downregulation reduced tubulointerstitial expression of CD206, the marker of M2 macrophages in diabetic mice. Thus, our findings indicate that tubular ATRAP-mediated functional modulation of angiotensin II type 1 receptor signaling modulates the accumulation of tubulointerstitial M2 macrophages, thus affecting glomerular manifestations of diabetic nephropathy via tubule-glomerular crosstalk.

    DOI： 10.1016/j.kint.2022.01.031

    PubMed

    researchmap

  • 5/6腎摘CKDモデルマウスを用いた高蛋白食負荷が腎障害に及ぼす影響についての検討

    田中 翔平, 涌井 広道, 大上 尚仁, 塚本 俊一郎, 浦手 進吾, 小林 竜, 小豆島 健護, 田村 功一

    日本腎臓学会誌   64 ( 3 )   253 - 253   2022.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 術後2年の待機期間を経て腎移植を行ったが、再発した腎癌の一例

    野田 竜之介, 釜野 大典, 安部 樹, 新沢 賢樹, 裴 有安, 小林 竜, 柳 麻衣, 石橋 由孝, 石川 晃

    日本臨床腎移植学会プログラム・抄録集   55回   234 - 234   2022.2

    　More details

    Language：Japanese   Publisher：(一社)日本臨床腎移植学会  

    researchmap

  • Granuloma formation after peritoneal dialysis catheter-related infection by Mycobacterium chelonae. International journal

    Ryunosuke Noda, Daisuke Kamano, Tatsuki Abe, Satoki Shinzawa, Manabu Takamatsu, Yuan Bae, Ryu Kobayashi, Mai Yanagi, Yoshitaka Ishibashi

    Kidney international   100 ( 6 )   1355 - 1355   2021.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.kint.2021.03.040

    PubMed

    researchmap

  • LDLアフェレシスが有効であった二次性膜性腎症の一例

    小林 竜, 柳 麻衣, 石橋 由孝, 蔵口 裕美, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本アフェレシス学会雑誌   40 ( Suppl. )   120 - 120   2021.10

    　More details

    Language：Japanese   Publisher：(一社)日本アフェレシス学会  

    researchmap

  • 同種造血幹細胞移植後8年で生じた膜性腎症の1例

    安部 樹, 釜野 大典, 新沢 賢樹, 野田 竜之介, 小林 竜, 柳 麻衣, 石橋 由孝

    日本腎臓学会誌   63 ( 6-E )   733 - 733   2021.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • PD関連腹膜炎発症予防に対する多職種連携の有効性

    野田 竜之介, 釜野 大典, 安部 樹, 新沢 賢樹, 小林 竜, 柳 麻衣, 石橋 由孝

    日本腎臓学会誌   63 ( 4 )   451 - 451   2021.6

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Prolonged shedding of SARS-CoV-2 in COVID-19 infected hemodialysis patients. International journal

    Shigeru Otsubo, Yumi Aoyama, Kayoko Kinoshita, Taijiro Goto, Yuriko Otsubo, Daisuke Kamano, Rena Sumura, Satoki Shinzawa, Tatsuki Abe, Ryunosuke Noda, Ryu Kobayashi, Mai Yanagi, Kosaku Nitta, Yoshitaka Ishibashi

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy   25 ( 3 )   356 - 358   2021.6

    　More details

  • Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy. International journal

    Takeo Ishii, Tomohiro Kumagae, Hiromichi Wakui, Shingo Urate, Shohei Tanaka, Eriko Abe, Toru Suzuki, Takahiro Yamaji, Sho Kinguchi, Ryu Kobayashi, Kotaro Haruhara, Takashi Nakamura, Shuzo Kobayashi, Kouichi Tamura

    FEBS open bio   11 ( 2 )   507 - 518   2021.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Xanthine oxidoreductase (XOR) is a critical enzyme in purine metabolism and uric acid production, and its levels are reported to increase during stress, thereby promoting organ damage. Herein, we investigated the activity of XOR in a mouse model of aristolochic acid I (AA)-induced nephropathy, a type of nephrotoxic chronic kidney disease (CKD). A persistent decrease in renal function was observed in mice up to 4 weeks after 4 weeks of AA (2.5 mg kg-1 ) administration. Renal histology revealed an increase in tubular interstitial fibrosis over time. Although AA administration did not change XOR activity in the plasma, heart, liver, or muscle, XOR activity was persistently increased in renal tissue. Our results suggest that the renal tissue-specific increase in XOR activity is involved in the progression of tubulo-interstitial disorders, specifically fibrosis.

    DOI： 10.1002/2211-5463.13083

    PubMed

    researchmap

  • A case of minimal change nephrotic syndrome with pregnancy.

    Mari Horigome, Ryu Kobayashi, Masaaki Hanaoka, Sho Kinguchi, Tomohiko Kanaoka, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura

    CEN case reports   10 ( 3 )   315 - 319   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A 32-year-old Japanese woman at 8 weeks of gestation was admitted to our hospital for systemic edema, hypoalbuminemia, and severe proteinuria. The patient had a history of generalized alopecia and migraine. We diagnosed nephrotic syndrome, and renal biopsy revealed minimal change nephrotic syndrome (MCNS). We administered 1000 mg/day of methylprednisolone for 3 days. Oral corticosteroid therapy was followed by 40 mg of prednisolone daily. We carefully selected concomitant medication after considering organogenesis. Before and after renal biopsy, we administered heparin, antithrombin III, and immunoglobulin agents as appropriate. The patient achieved complete remission on day 8 of treatment and gave birth to a boy at 37 weeks of gestation without recurrence. MCNS during pregnancy is rare, and there is no established treatment. In conclusion, we present a case of a pregnant woman with MCNS during organogenesis. Early treatment initiation can provide a good prognosis for both mother and child.

    DOI： 10.1007/s13730-020-00568-5

    PubMed

    researchmap

  • Effect of renin-angiotensin system blockers on contrast-induced acute kidney injury in patients with normal or mild-to-moderate reduced kidney function undergoing coronary angiography: A systematic review and meta-analysis. International journal

    Takayuki Yamada, Tomohiro Fujisaki, Nitin Chopra, Takahiro Yamaji, Kengo Azushima, Ryu Kobayashi, Sho Kinguchi, Shingo Urate, Toru Suzuki, Eriko Abe, Hiromichi Wakui, Kouichi Tamura, Daniel Steinberg

    Clinical nephrology   94 ( 5 )   227 - 236   2020.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Contrast-induced acute kidney injury (CI-AKI) is a major complication after coronary angiography (CAG) or percutaneous coronary intervention (PCI) and is associated with increased morbidity and mortality. It remains controversial whether renin-angiotensin system (RAS) blockers increase or decrease CI-AKI. In this meta-analysis, we investigated the association between RAS blockers and CI-AKI in patients with normal kidney function or mild-to-moderate chronic kidney disease (CKD). MATERIALS AND METHODS: We performed a systematic search of PubMed, EMBASE, clinicaltrials.gov, and the Cochrane Library up to December 2019 for studies that assessed the association between RAS blockers and CI-AKI events after CAG/PCI. The primary outcome was the development of CI-AKI. Odds ratios (ORs) with corresponding 95% confidence interval (CI) were synthesized. RESULTS: Five randomized controlled trials (RCTs) and five observational studies were included, accounting for a total of 7,420 patients. Unstratified, RAS blocker administration was significantly associated with an increased risk of CI-AKI (pooled OR = 1.63, 95% CI 1.19 - 2.25, p = 0.003). However, the effect was not observed in RCTs (pooled OR = 1.22, 95% CI 0.54 - 2.74, p = 0.63). Sensitivity analysis in observational studies showed significant association (pooled OR = 1.77, 95% CI 1.22 - 2.55, p = 0.003) with high heterogeneity and evidence of publication bias. CONCLUSION: In patients with relatively-preserved renal function, the association of RAS blockers with an increased risk of CI-AKI after contrast media exposure was inconclusive, as sensitivity analysis showed conflicting results and bias. Although this study did not demonstrate significant evidence, it indicated that clinicians need to be vigilant in assessing the potential risk for RAS blockers to cause CI-AKI in low-risk patients.

    DOI： 10.5414/CN110171

    PubMed

    researchmap

  • 非定型抗酸菌による腹膜透析カテーテル感染の4例

    平塚 梨奈, 堀米 麻里, 植田 瑛子, 花岡 正哲, 岩野 剛久, 鈴木 将太, 金口 翔, 小林 竜, 金岡 知彦, 柳 麻衣, 涌井 広道, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   53 ( Suppl.1 )   384 - 384   2020.10

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • アトピー性皮膚炎に伴う掻爬により出口部感染を繰り返した腹膜透析患者に対してデュピルマブを導入した一例

    野田 竜之介, 釜野 大典, 安部 樹, 新沢 賢樹, 寸村 玲奈, 小林 竜, 柳 麻衣, 石橋 由孝

    日本腎臓学会誌   62 ( 6 )   560 - 560   2020.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 妊娠初期にネフローゼ症候群を発症しステロイドにより寛解が得られた一例

    堀米 麻里, 小林 竜, 花岡 正哲, 金口 翔, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   62 ( 6 )   653 - 653   2020.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure. International journal

    Takayuki Yamada, Hiroki Ueyama, Nitin Chopra, Takahiro Yamaji, Kengo Azushima, Ryu Kobayashi, Sho Kinguchi, Shingo Urate, Toru Suzuki, Eriko Abe, Yusuke Saigusa, Hiromichi Wakui, Paulina Partridge, Alfred Burger, Claudio A Bravo, Maria A Rodriguez, Juan Ivey-Miranda, Kouichi Tamura, Jeffery Testani, Steven Coca

    Kidney international reports   5 ( 9 )   1486 - 1494   2020.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Introduction: Outcomes in acute decompensated heart failure (ADHF) have remained poor. Worsening renal function (WRF) is common among patients with ADHF. However, the impact of WRF on the prognosis is controversial. We hypothesized that in patients with ADHF, the achievement of concomitant decongestion would diminish the signal for harm associated with WRF. Methods: We performed a systematic search of PubMed, EMBASE, and the Cochrane Library up to December 2019 for studies that assessed signs of decongestion in patients with WRF during ADHF admission. The primary outcome was all-cause mortality and heart transplantation. Results: Thirteen studies were selected with a pooled population of 8138 patients. During the follow-up period of 60-450 days, 19.2% of patients died. Unstratified, patients with WRF versus no WRF had a higher risk for mortality (odds ratio [OR], 1.71 [95% confidence interval {CI}, 1.45-2.01]; P < 0.0001). However, patients who achieved decongestion had a similar prognosis (OR, 1.15 [95% CI, 0.89-1.49]; P = 0.30). Moreover, patients with WRF who achieved decongestion had a better prognosis compared with those without WRF or decongestion (OR, 0.63 [95% CI, 0.46-0.86]; P = 0.004). This tendency persisted for the sensitivity analyses. Conclusions: Decongestion is a powerful effect modifier that attenuates harmful associations of WRF with mortality. Future studies should not assess WRF as an endpoint without concomitant assessment of achieved volume status.

    DOI： 10.1016/j.ekir.2020.06.031

    PubMed

    researchmap

  • 当院における末期腎不全合併COVID-19患者9名の臨床的特徴

    安部 樹, 寸村 玲奈, 新沢 賢樹, 野田 竜之介, 釜野 大典, 小林 竜, 柳 麻衣, 石橋 由孝

    日本腎臓学会誌   62 ( 6 )   564 - 564   2020.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 5/6腎摘慢性腎臓病モデルマウスによる高血圧とアンジオテンシン受容体結合因子(ATRAP)の関係についての検討

    田中 翔平, 小林 竜, 涌井 広道, 山地 孝拡, 鈴木 徹, 浦手 進吾, 安部 えりこ, 金口 翔, 小豆島 健護, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   62 ( 4 )   370 - 370   2020.7

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia. International journal

    Kohji Ohki, Hiromichi Wakui, Kazushi Uneda, Kengo Azushima, Kotaro Haruhara, Sho Kinguchi, Shingo Urate, Takayuki Yamada, Takahiro Yamaji, Ryu Kobayashi, Tomohiko Kanaoka, Shintaro Minegishi, Tomoaki Ishigami, Tetsuya Fujikawa, Yoshiyuki Toya, Kouichi Tamura

    Kidney diseases (Basel, Switzerland)   6 ( 4 )   299 - 308   2020.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Introduction: Erythropoietin-stimulating agents (ESAs) are used to treat renal anemia in patients with non-dialysis CKD, but this can lead to increases in blood pressure (BP). Objective: We investigated the effects of continuous erythropoietin receptor activator (CERA) and darbepoetin alfa (DA) on office/ambulatory BP in 36 patients with non-dialysis CKD and renal anemia who did not receive ESA treatment. Methods: Participants were randomly assigned to CERA or DA, and received ESA treatment for 24 weeks. ESA doses were adjusted to maintain hemoglobin (Hb) at 10-12 g/dL. Primary outcomes were office/ambulatory BP after 24 weeks of ESA treatment. Hb levels were within the target range at 24 weeks. Results: Office/ambulatory BP, renal function, and other parameters were not significantly different between groups. However, we could not exclude the possibility that differences may exist because our sample size was small. Therefore, we also performed analysis of all of the data that were compiled from the groups of per-protocol population. Although office/ambulatory BP profiles had not worsened after 24 weeks of ESA treatment, more than half of the patients required an increase in the antihypertensive agent dose. Conclusions: CERA and DA may have similar effects on BP profiles in patients with non-dialysis CKD and renal anemia. ESA treatment often requires increases in the doses of antihypertensive agents.

    DOI： 10.1159/000507396

    PubMed

    researchmap

  • アリストロキア酸腎症の加齢性変化についての検討

    浦手 進吾, 涌井 広道, 山地 孝拡, 田中 翔平, 安部 えりこ, 金口 翔, 小林 竜, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   62 ( 4 )   335 - 335   2020.7

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • AT1R結合タンパク質ATRAPの結合タンパク質探索による分子機能解析

    安部 えりこ, 涌井 広道, 山下 暁朗, 山地 孝拡, 浦手 進吾, 田中 翔平, 鈴木 徹, 金口 翔, 小林 竜, 小豆島 健護, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   62 ( 4 )   369 - 369   2020.7

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Effects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in mice. Reviewed International journal

    Hiromichi Wakui, Takahiro Yamaji, Kengo Azushima, Kazushi Uneda, Kotaro Haruhara, Akiko Nakamura, Kohji Ohki, Sho Kinguchi, Ryu Kobayashi, Shingo Urate, Toru Suzuki, Daisuke Kamimura, Shintaro Minegishi, Tomoaki Ishigami, Tomohiko Kanaoka, Kohei Matsuo, Tomoyuki Miyazaki, Tetsuya Fujikawa, Akio Yamashita, Kouichi Tamura

    Scientific reports   10 ( 1 )   1782 - 1782   2020.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Chronic kidney disease (CKD) progresses to end-stage renal failure via renal tubulointerstitial fibrosis. Malnutrition, inflammation, and arteriosclerosis interact to exacerbate the poor prognosis of CKD, and their effective management is thus essential. The traditional Japanese medicine Rikkunshito (RKT) exerts appetite-stimulating effects via ghrelin, which attenuates inflammation and fibrosis. We evaluated the therapeutic effect of RKT in unilateral ureter obstruction (UUO)-induced renal fibrosis/inflammation and body weight loss in mice. UUO and sham-operated mice were fed a standard diet or diet containing 3.0% RKT. Renal fibrosis was investigated by histopathology and macrophage infiltration was determined by immunohistochemistry. Expression levels of genes associated with fibrosis, inflammation, ghrelin, and mitochondrial function were determined by quantitative reverse transcription-polymerase chain reaction and western blot analyses. RKT treatment partially prevented UUO-induced weight loss but failed to attenuate renal fibrosis and inflammation. Renal expression of sirtuin 1, a ghrelin-downstream signalling molecule, and gene expression of peroxisome proliferator-activated receptor-γ coactivator 1α and Bcl-2/adenovirus E1B interacting protein 3 were unaffected by RKT. These results indicate that RKT inhibits weight loss but does not improve renal fibrosis or inflammation in a rapidly progressive renal fibrosis mouse model. RKT may have a protective effect on weight loss associated with CKD.

    DOI： 10.1038/s41598-020-58214-0

    PubMed

    researchmap

  • Angiotensin II type 1 receptor-associated protein deficiency attenuates sirtuin1 expression in an immortalised human renal proximal tubule cell line. Reviewed International journal

    Takahiro Yamaji, Akio Yamashita, Hiromichi Wakui, Kengo Azushima, Kazushi Uneda, Yumiko Fujikawa, Sona Haku, Ryu Kobayashi, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Takeo Ishii, Takayuki Yamada, Shingo Urate, Toru Suzuki, Eriko Abe, Shohei Tanaka, Daisuke Kamimura, Tomoaki Ishigami, Yoshiyuki Toya, Hidehisa Takahashi, Kouichi Tamura

    Scientific reports   9 ( 1 )   16550 - 16550   2019.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The proximal tubule is a particularly important site for ageing-related kidney damage. Sirtuin 1 (SIRT1), an NAD+ (nicotinamide adenine dinucleotide)-dependent deacetylase in the proximal tubule, may be involved in renal injury associated with ageing. However, the mechanisms of SIRT1 regulation remain to be elucidated. We recently reported that angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP)-deficient mice displayed age-associated renal function decline and tubulointerstitial fibrosis. Our data showed that SIRT1 protein expression was reduced in ATRAP-deficient mice, although the relationship between ATRAP deficiency and age-associated renal fibrosis is still not fully understood. It is, therefore, necessary to investigate how ATRAP affects SIRT1 protein expression to resolve ageing-associated kidney dysfunction. Here, since ageing studies are inherently lengthy, we used an ex vivo model of the proximal tubule to determine the role of ATRAP in SIRT1 protein expression. We first generated a clonal immortalised human renal proximal tubule epithelial cell line (ciRPTEC) expressing AT1R and ATRAP. Using this cell line, we demonstrated that ATRAP knockdown reduced SIRT1 protein expression in the ciRPTEC but did not alter SIRT1 mRNA expression. Thus, ATRAP likely mediates SIRT1 protein abundance in ciRPTEC.

    DOI： 10.1038/s41598-019-52566-y

    PubMed

    researchmap

  • 腎近位尿細管AT1受容体結合因子がアンジオテンシン依存性高血圧に及ぼす影響(Effects of AT1 Receptor-Associated Protein in Renal Proximal Tubules on Angiotensin II-Mediated Hypertension)

    金口 翔, 涌井 広道, 小豆島 健護, 春原 浩太郎, 高口 知之, 大城 光二, 畝田 一司, 白 善雅, 山地 孝拡, 山田 貴之, 小林 竜, 石上 友章, 山下 暁朗, 藤川 哲也, 田村 功一

    日本高血圧学会総会プログラム・抄録集   42回   200 - 200   2019.10

    　More details

    Language：English   Publisher：(NPO)日本高血圧学会  

    researchmap

  • Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Reviewed International journal

    Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi, Kazutaka Aoki, Gen Yasuda, Taishi Yoshii, Takayuki Yamada, Syuji Ono, Tomoko Shibasaki-Kurita, Saho Hosokawa, Kazuki Orime, Masaaki Hanaoka, Hiroto Sasaki, Kohji Inazumi, Taku Yamada, Ryu Kobayashi, Kohji Ohki, Kotaro Haruhara, Yusuke Kobayashi, Takeharu Yamanaka, Yasuo Terauchi, Kouichi Tamura

    Cardiovascular diabetology   18 ( 1 )   110 - 110   2019.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: The Y-AIDA study was designed to investigate the renal- and home blood pressure (BP)-modulating effects of add-on dapagliflozin treatment in Japanese individuals with type 2 diabetes mellitus (T2DM) and albuminuria. METHODS: We conducted a prospective, multicenter, single-arm study. Eighty-six patients with T2DM, HbA1c 7.0-10.0%, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2, and urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g creatinine (gCr) were enrolled, and 85 of these patients were administered add-on dapagliflozin for 24 weeks. The primary and key secondary endpoints were change from baseline in the natural logarithm of UACR over 24 weeks and change in home BP profile at week 24. RESULTS: Baseline median UACR was 181.5 mg/gCr (interquartile range 47.85, 638.0). Baseline morning, evening, and nocturnal home systolic/diastolic BP was 137.6/82.7 mmHg, 136.1/79.3 mmHg, and 125.4/74.1 mmHg, respectively. After 24 weeks, the logarithm of UACR decreased by 0.37 ± 0.73 (P < 0.001). In addition, changes in morning, evening, and nocturnal home BP from baseline were as follows: morning systolic/diastolic BP - 8.32 ± 11.42/- 4.18 ± 5.91 mmHg (both P < 0.001), evening systolic/diastolic BP - 9.57 ± 12.08/- 4.48 ± 6.45 mmHg (both P < 0.001), and nocturnal systolic/diastolic BP - 2.38 ± 7.82/- 1.17 ± 5.39 mmHg (P = 0.0079 for systolic BP, P = 0.0415 for diastolic BP). Furthermore, the reduction in UACR after 24 weeks significantly correlated with an improvement in home BP profile, but not with changes in other variables, including office BP. Multivariate linear regression analysis also revealed that the change in morning home systolic BP was a significant contributor to the change in log-UACR. CONCLUSIONS: In Japanese patients with T2DM and diabetic nephropathy, dapagliflozin significantly improved albuminuria levels and the home BP profile. Improved morning home systolic BP was associated with albuminuria reduction. Trial registration The study is registered at the UMIN Clinical Trials Registry (UMIN000018930; http://www.umin.ac.jp/ctr/index-j.htm ). The study was conducted from July 1, 2015 to August 1, 2018.

    DOI： 10.1186/s12933-019-0912-3

    PubMed

    researchmap

  • Effects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused mice. Reviewed International journal

    Kengo Azushima, Kazushi Uneda, Hiromichi Wakui, Kohji Ohki, Kotaro Haruhara, Ryu Kobayashi, Sona Haku, Sho Kinguchi, Takahiro Yamaji, Shintaro Minegishi, Tomoaki Ishigami, Akio Yamashita, Kouichi Tamura

    Scientific reports   9 ( 1 )   6201 - 6201   2019.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-019-42657-1

    Web of Science

    PubMed

    researchmap

  • Effects of ATRAP in Renal Proximal Tubules on Angiotensin-Dependent Hypertension. Reviewed International journal

    Sho Kinguchi, Hiromichi Wakui, Kengo Azushima, Kotaro Haruhara, Tomoyuki Koguchi, Kohji Ohki, Kazushi Uneda, Miyuki Matsuda, Sona Haku, Takahiro Yamaji, Takayuki Yamada, Ryu Kobayashi, Shintaro Minegishi, Tomoaki Ishigami, Akio Yamashita, Tetsuya Fujikawa, Kouichi Tamura

    Journal of the American Heart Association   8 ( 8 )   e012395   2019.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Background We have previously shown that ATRAP (angiotensin II receptor-associated protein; Agtrap) interacts with AT1R (angiotensin II type 1 receptor) and promotes constitutive internalization of AT 1R so as to inhibit hyperactivation of its downstream signaling. In response to angiotensin II , systemic ATRAP deficiency exacerbates angiotensin II -mediated hypertension via hyperactivation of renal tubular AT 1R. Although ATRAP expression is abundant in renal proximal tubules, little is known about the actual function of renal proximal tubule ATRAP in angiotensin-mediated hypertension. Methods and Results In this study, we examined the in vivo functional role of renal proximal tubule ATRAP in angiotensin-dependent hypertension. We succeeded in generating proximal tubule-specific ATRAP knockout ( PT - KO ) mice for the first time using the Cre/loxP system with Pepck-Cre. Detailed analysis of renal ATRAP expression in PT - KO mice estimated by immunohistochemical and laser-capture microdissection analysis revealed that ATRAP mRNA expression decreased by ≈80% in proximal regions of the nephron in PT - KO mice compared with wild-type ( WT ) mice. We compared blood pressure of PT - KO and WT mice using both tail-cuff and radiotelemetric methods. Blood pressure of PT - KO mice was comparable with that of WT mice at baseline. Moreover, no significant differences were noted in pressor response to angiotensin II (600 ng/kg per min or 1000 ng/kg per minute) infusion between PT - KO and WT mice. In addition, angiotensin II -mediated cardiac hypertrophy was identical between PT - KO and WT mice. Conclusions ATRAP deficiency in proximal tubules did not exacerbate angiotensin-dependent hypertension in vivo. The results indicate that renal proximal tubule ATRAP has a minor role in angiotensin-dependent hypertension in vivo.

    DOI： 10.1161/JAHA.119.012395

    PubMed

    researchmap

  • 頻回再発型MCNSに対しプレドニゾロンとリツキシマブが併用された患者にニューモシスチス肺炎を認めた症例

    大上 尚仁, 小林 竜, 春原 須美玲, 平塚 梨奈, 花岡 正哲, 大城 光二, 畝田 一司, 金岡 知彦, 橋本 達夫, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   60 ( 6 )   872 - 872   2018.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue. Reviewed International journal

    Kohji Ohki, Hiromichi Wakui, Nozomu Kishio, Kengo Azushima, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kotaro Haruhara, Sho Kinguchi, Takahiro Yamaji, Takayuki Yamada, Shintaro Minegishi, Tomoaki Ishigami, Yoshiyuki Toya, Akio Yamashita, Kento Imajo, Atsushi Nakajima, Ikuma Kato, Kenichi Ohashi, Kouichi Tamura

    Scientific reports   8 ( 1 )   2846 - 2846   2018.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Enhancement of AT1 receptor-associated protein (ATRAP) in adipose tissue improves high fat diet (HFD)-induced visceral obesity and insulin resistance, and suppresses adipose oxidative stress. However, HFD loading is not a direct stimulatory factor for AT1 receptor. In the present study, we investigated the effect of chronic, low-dose angiotensin II (Ang II) stimulation on glucose and lipid metabolism in mice and functional role of ATRAP. ATRAP expression was higher in adipose tissue (5-10-fold) and skeletal muscle tissue (approximately 1.6-fold) in ATRAP transgenic (TG) mice compared with wild-type (WT) mice. After Ang II infusion, insulin sensitivity was impaired in WT mice, but this response was suppressed in TG mice. Unexpectedly, Ang II infusion did not affect the adipose tissue profile in WT or TG mice. However, in skeletal muscle tissue, Ang II stimulus caused an increase in oxidative stress and activation of p38 MAPK, resulting in a decrease in glucose transporter type 4 expression in WT mice. These responses were suppressed in TG mice. Our study suggests that Ang II-induced insulin resistance is suppressed by increased ATRAP expression in skeletal muscle tissue. Hyperactivity of AT1 receptor could be related to formation of insulin resistance related to metabolic syndrome.

    DOI： 10.1038/s41598-018-21270-8

    PubMed

    researchmap

  • Angiotensin receptor-binding molecule in leukocytes in association with the systemic and leukocyte inflammatory profile. Reviewed International journal

    Kotaro Haruhara, Hiromichi Wakui, Kengo Azushima, Daisuke Kurotaki, Wataru Kawase, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kohji Ohki, Sho Kinguchi, Masato Ohsawa, Shintaro Minegishi, Tomoaki Ishigami, Miyuki Matsuda, Akio Yamashita, Hideaki Nakajima, Tomohiko Tamura, Nobuo Tsuboi, Takashi Yokoo, Kouichi Tamura

    Atherosclerosis   269   236 - 244   2018.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND AND AIMS: The components of the renin-angiotensin system in leukocytes is involved in the pathophysiology of non-communicable diseases (NCDs), including hypertension, atherosclerosis and chronic kidney disease. Angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP) is an AT1R-specific binding protein, and is able to inhibit the pathological activation of AT1R signaling in certain animal models of NCDs. The aim of the present study was to investigate the expression and regulation of ATRAP in leukocytes. METHODS: Human leukocyte ATRAP mRNA was measured with droplet digital polymerase chain reaction system, and analyzed in relation to the clinical variables. We also examined the leukocyte cytokines mRNA in bone-marrow ATRAP-deficient and wild-type chimeric mice after injection of low-dose lipopolysaccharide. RESULTS: The ATRAP mRNA was abundantly expressed in leukocytes, predominantly granulocytes and monocytes, of healthy subjects. In 86 outpatients with NCDs, leukocyte ATRAP mRNA levels correlated positively with granulocyte and monocyte counts and serum C-reactive protein levels. These positive relationships remained significant even after adjustment. Furthermore, the leukocyte ATRAP mRNA was significantly associated with the interleukin-1β, tumor necrosis factor-α and monocyte chemotactic protein-1 mRNA levels in leukocytes of NCDs patients. In addition, the leukocyte interleukin-1β mRNA level was significantly upregulated in bone marrow ATRAP-deficient chimeric mice in comparison to wild-type chimeric mice after injection of lipopolysaccharide. CONCLUSIONS: These results suggest that leukocyte ATRAP is an emerging marker capable of reflecting the systemic and leukocyte inflammatory profile, and plays a role as an anti-inflammatory factor in the pathophysiology of NCDs.

    DOI： 10.1016/j.atherosclerosis.2018.01.013

    PubMed

    researchmap

  • Early Enhanced Leucine-Rich α-2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice. Reviewed International journal

    Sona Haku, Hiromichi Wakui, Kengo Azushima, Kotaro Haruhara, Sho Kinguchi, Kohji Ohki, Kazushi Uneda, Ryu Kobayashi, Miyuki Matsuda, Takahiro Yamaji, Takayuki Yamada, Shintaro Minegishi, Tomoaki Ishigami, Akio Yamashita, Kenichi Ohashi, Kouichi Tamura

    BioMed research international   2018   2817045 - 2817045   2018

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1155/2018/2817045

    Web of Science

    PubMed

    researchmap

  • Angiotensin II Type 1 Receptor-Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin. Reviewed International journal

    Kazushi Uneda, Hiromichi Wakui, Akinobu Maeda, Kengo Azushima, Ryu Kobayashi, Sona Haku, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Miyuki Matsuda, Masato Ohsawa, Shintaro Minegishi, Tomoaki Ishigami, Yoshiyuki Toya, Yoshitoshi Atobe, Akio Yamashita, Satoshi Umemura, Kouichi Tamura

    Journal of the American Heart Association   6 ( 8 )   2017.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: The kidney is easily affected by aging-associated changes, including glomerulosclerosis, tubular atrophy, and interstitial fibrosis. Particularly, renal tubulointerstitial fibrosis is a final common pathway in most forms of progressive renal disease. Angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP), which was originally identified as a molecule that binds to AT1R, is highly expressed in the kidney. Previously, we have shown that ATRAP suppresses hyperactivation of AT1R signaling, but does not affect physiological AT1R signaling. METHODS AND RESULTS: We hypothesized that ATRAP has a novel functional role in the physiological age-degenerative process, independent of modulation of AT1R signaling. ATRAP-knockout mice were used to study the functional involvement of ATRAP in the aging. ATRAP-knockout mice exhibit a normal age-associated appearance without any evident alterations in physiological parameters, including blood pressure and cardiovascular and metabolic phenotypes. However, in ATRAP-knockout mice compared with wild-type mice, the following takes place: (1) age-associated renal function decline and tubulointerstitial fibrosis are more enhanced; (2) renal tubular mitochondrial abnormalities and subsequent increases in the production of reactive oxygen species are more advanced; and (3) life span is 18.4% shorter (median life span, 100.4 versus 123.1 weeks). As a key mechanism, age-related pathological changes in the kidney of ATRAP-knockout mice correlated with decreased expression of the prosurvival gene, Sirtuin1. On the other hand, chronic angiotensin II infusion did not affect renal sirtuin1 expression in wild-type mice. CONCLUSIONS: These results indicate that ATRAP plays an important role in inhibiting kidney aging, possibly through sirtuin1-mediated mechanism independent of blocking AT1R signaling, and further protecting normal life span.

    DOI： 10.1161/JAHA.117.006120

    PubMed

    researchmap

  • Enhancement of intrarenal plasma membrane calcium pump isoform 1 expression in chronic angiotensin II-infused mice. Reviewed International journal

    Hiromichi Wakui, Koichiro Sumida, Megumi Fujita, Yuta Ohtomo, Masato Ohsawa, Ryu Kobayashi, Kazushi Uneda, Kengo Azushima, Kotaro Haruhara, Keisuke Yatsu, Nobuhito Hirawa, Shintaro Minegishi, Tomoaki Ishigami, Satoshi Umemura, Kouichi Tamura

    Physiological reports   5 ( 11 )   2017.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Plasma membrane calcium pump isoform 1 (PMCA1) is encoded by ATPase plasma membrane Ca
    2+
    transporting 1 (ATP2B1), the most likely candidate gene responsible for hypertension. Although PMCA1 is highly expressed in the kidney, little is known about regulation of its renal expression in various pathological conditions in vivo. Our study was designed to elucidate regulation of renal PMCA1 expression in mice. We employed three mouse models for kidney disease. These were the unilateral ureteral obstruction (UUO), the remnant kidney using 5/6 nephrectomy, and chronic angiotensin II administration models. Mice were assessed for systolic blood pressure and renal injury in accordance with the damage induced in the specific model. Kidney PMCA1 mRNA levels were measured in all mice. The UUO model showed renal fibrosis but no changes in blood pressure or renal PMCA1 mRNA expression. Similarly, the 5/6 nephrectomy model exhibited declined renal function without changes in blood pressure or renal PMCA1 mRNA expression. In contrast, chronic angiotensin II administration increased albuminuria and blood pressure as well as significantly increasing renal PMCA1 mRNA and protein expression. These results suggest that renal PMCA1 has a role as one of the molecules involved in angiotensin II-induced hypertension and kidney injury.

    DOI： 10.14814/phy2.13316

    PubMed

    researchmap

  • An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model Reviewed International journal

    Ryu Kobayashi, Hiromichi Wakui, Kengo Azushima, Kazushi Uneda, Sona Haku, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Miyuki Matsuda, Masato Ohsawa, Yoshiyuki Toya, Akira Nishiyama, Akio Yamashita, Katsuyuki Tanabe, Yohei Maeshima, Satoshi Umemura, Kouichi Tamura

    KIDNEY INTERNATIONAL   91 ( 5 )   1115 - 1125   2017.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.kint.2016.10.035

    Web of Science

    PubMed

    researchmap

  • ATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice. Reviewed International journal

    Kohji Ohki, Hiromichi Wakui, Kengo Azushima, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kotaro Haruhara, Sho Kinguchi, Miyuki Matsuda, Masato Ohsawa, Akinobu Maeda, Shintaro Minegishi, Tomoaki Ishigami, Yoshiyuki Toya, Akio Yamashita, Satoshi Umemura, Kouichi Tamura

    International journal of molecular sciences   18 ( 3 )   2017.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Activation of tissue renin-angiotensin system (RAS), mainly mediated by an angiotensin II (Ang II) type 1 receptor (AT1R), plays an important role in the development of obesity-related metabolic disorders. We have shown that AT1R-associated protein (ATRAP), a specific binding protein of AT1R, functions as an endogenous inhibitor to prevent excessive activation of tissue RAS. In the present study, we newly generated ATRAP/Agtrap-floxed (ATRAPfl/fl) mice and adipose tissue-specific ATRAP downregulated (ATRAPadipoq) mice by the Cre/loxP system using Adipoq-Cre. Using these mice, we examined the functional role of adipose ATRAP in the pathogenesis of obesity-related metabolic disorders. Compared with ATRAPfl/fl mice, ATRAPadipoq mice exhibited a decreased ATRAP expression in visceral white adipose tissue (WAT) and brown adipose tissue (BAT) by approximately 30% and 85%, respectively. When mice were fed a high-fat diet, ATRAPfl/fl mice showed decreased endogenous ATRAP expression in WAT that was equivalent to ATRAPadipoq mice, and there was no difference in the exacerbation of dietary obesity and glucose and lipid metabolism. These results indicate that ATRAP in BAT does not influence the pathogenesis of dietary obesity or metabolic disorders. Future studies that modulate ATRAP in WAT are necessary to assess its in vivo functions in the development of obesity-related metabolic disorders.

    DOI： 10.3390/ijms18030676

    PubMed

    researchmap

  • Adipocyte-Specific Enhancement of Angiotensin II Type 1 Receptor-Associated Protein Ameliorates Diet-Induced Visceral Obesity and Insulin Resistance Reviewed International journal

    Kengo Azushima, Kohji Ohki, Hiromichi Wakui, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kotaro Haruhara, Sho Kinguchi, Miyuki Matsuda, Akinobu Maeda, Yoshiyuki Toya, Akio Yamashita, Satoshi Umemura, Kouichi Tamura

    JOURNAL OF THE AMERICAN HEART ASSOCIATION   6 ( 3 )   2017.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1161/JAHA.116.004488

    Web of Science

    PubMed

    researchmap

  • Within-visit blood pressure variability and cardiovascular risk factors in hypertensive patients with non-dialysis chronic kidney disease Reviewed International journal

    Kengo Azushima, Hiromichi Wakui, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kohji Ohki, Sho Kinguchi, Kotaro Haruhara, Tetsuya Fujikawa, Yoshiyuki Toya, Satoshi Umemura, Kouichi Tamura

    CLINICAL AND EXPERIMENTAL HYPERTENSION   39 ( 7 )   665 - 671   2017

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10641963.2017.1313850

    Web of Science

    PubMed

    researchmap

  • Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition Reviewed International journal

    Kouichi Tamura, Ryu Kobayashi, Sona Haku, Kengo Azushima, Hiromichi Wakui

    HYPERTENSION RESEARCH   39 ( 11 )   753 - 755   2016.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/hr.2016.71

    Web of Science

    PubMed

    researchmap

  • AT1受容体直接結合因子ATRAPのヒト末梢血白血球における遺伝子発現と臨床指標との関連

    春原 浩太郎, 田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 白 善雅, 小林 竜, 大城 光二, 金口 翔, 松田 みゆき, 山下 暁朗, 坪井 伸夫, 横尾 隆, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   39回   374 - 374   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease Reviewed International journal

    Kazushi Uneda, Kouichi Tamura, Hiromichi Wakui, Kengo Azushima, Sona Haku, Ryu Kobayashi, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Masato Ohsawa, Tetsuya Fujikawa, Satoshi Umemura

    CLINICAL AND EXPERIMENTAL HYPERTENSION   38 ( 8 )   738 - 743   2016

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10641963.2016.1200064

    Web of Science

    PubMed

    researchmap

  • Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases Reviewed International journal

    Ryu Kobayashi, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Kengo Azushima, Sona Haku, Kazushi Uneda, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Satoshi Umemura

    CLINICAL AND EXPERIMENTAL HYPERTENSION   38 ( 8 )   744 - 750   2016

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10641963.2016.1200063

    Web of Science

    PubMed

    researchmap

  • Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia Reviewed International journal

    Masato Ohsawa, Kouichi Tamura, Hiromichi Wakui, Tomohiko Kanaoka, Kengo Azushima, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Yoshiyuki Toya, Satoshi Umemura

    LIPIDS IN HEALTH AND DISEASE   14   161 - 161   2015.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s12944-015-0164-5

    Web of Science

    PubMed

    researchmap

  • TLR4 as a possible key regulator of pathological vascular remodeling by Ang II receptor activation Reviewed International journal

    Kouichi Tamura, Tomohiko Kanaoka, Ryu Kobayashi, Kohji Ohki, Masato Ohsawa

    HYPERTENSION RESEARCH   38 ( 10 )   642 - 643   2015.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/hr.2015.65

    Web of Science

    PubMed

    researchmap

  • Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension: A multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2) Reviewed International journal

    Kengo Azushima, Kouichi Tamura, Sona Haku, Hiromichi Wakui, Tomohiko Kanaoka, Masato Ohsawa, Kazushi Uneda, Ryu Kobayashi, Kohji Ohki, Toru Dejima, Akinobu Maeda, Tatsuo Hashimoto, Jin Oshikawa, Yusuke Kobayashi, Koichiro Nomura, Chieko Azushima, Yasuyo Takeshita, Ryota Fujino, Ken Uchida, Ken Shibuya, Daisaku Ando, Yasuo Tokita, Tetsuya Fujikawa, Yoshiyuki Toya, Satoshi Umemura

    ATHEROSCLEROSIS   240 ( 1 )   297 - 304   2015.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.atherosclerosis.2015.01.025

    Web of Science

    PubMed

    researchmap

  • Renal Tubule Angiotensin II Type 1 Receptor-Associated Protein Promotes Natriuresis and Inhibits Salt-Sensitive Blood Pressure Elevation Reviewed International journal

    Hiromichi Wakui, Kazushi Uneda, Kouichi Tamura, Masato Ohsawa, Kengo Azushima, Ryu Kobayashi, Kohji Ohki, Toru Dejima, Tomohiko Kanaoka, Yuko Tsurumi-Ikeya, Miyuki Matsuda, Kotaro Haruhara, Akira Nishiyama, Machiko Yabana, Tetsuya Fujikawa, Akio Yamashita, Satoshi Umemura

    JOURNAL OF THE AMERICAN HEART ASSOCIATION   4 ( 3 )   e001594   2015.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1161/JAHA.114.001594

    Web of Science

    PubMed

    researchmap

  • Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology Reviewed

    K. Tamura, H. Wakui, K. Azushima, K. Uneda, S. Haku, R. Kobayashi, K. Ohki, K. Haruhara, S. Kinguchi, M. Matsuda, A. Yamashita, S. Umemura

    CURRENT MEDICINAL CHEMISTRY   22 ( 28 )   3210 - 3216   2015

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.2174/0929867322666150821095036

    Web of Science

    researchmap

  • Therapeutic impact of the single fixed-dose combination with a high-dose angiotensin-receptor blocker and a low-dose thiazide diuretic in the management of hypertension: awaiting further accumulation of clinical evidence Reviewed International journal

    Kouichi Tamura, Koji Ohki, Ryu Kobayashi, Kazushi Uneda, Kengo Azushima, Masato Ohsawa, Hiromichi Wakui, Masashi Sakai, Yasuo Tokita, Satoshi Umemura

    HYPERTENSION RESEARCH   37 ( 12 )   1032 - 1034   2014.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/hr.2014.130

    Web of Science

    PubMed

    researchmap

  • [Video-assisted thoracoscopic surgery for pleuroperitoneal communications as a complication of continuous ambulatory peritoneal dialysis( CAPD)]. Reviewed

    Tsuchiya T, Sano A, Fukami T, Yanagi M, Yoshiura T, Kobayashi R

    Kyobu geka. The Japanese journal of thoracic surgery   67 ( 11 )   963 - 966   2014.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    A 54-year-old female who was started on continuous ambulatory peritoneal dialysis( CAPD) for endstage renal disease secondary to focal developed 2 pleuroperitoneal communications. At first, she developed chest pain and cough on the day following introduction. A 99m-technetium-macroaggregated albumin (99mTc-MAA) radionuclide scan showed a communication between the abdomen and the right pleural cavity. We diagnosed a right pleuroperitoneal communication. Four months later, she developed similar symptoms and was diagnosed with a left pleuroperitoneal communication. Video-assisted thoracoscopic surgery was performed for each lesion. However, the communications were detected using different methods. During the 1st surgery, the communication was detected using peritoneal dialysis fluid containing indigocarmine introduced through a CAPD catheter. During the 2nd surgery, the communication was detected by pneumoperitoneum. With regards to diaphragmatic pressure regulation, pneumoperitoneum was more rapid and convenient, so pneumoperitoneum was considered more effective for the identification and treatment of pleuroperitoneal communications. Diaphragmatic plication and pleurodesis with polyglycolic acid felt and fibrin glue on both sides were performed. No recurrence of hydrothorax was detected after treatment.

    PubMed

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2015008973

  • Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension Reviewed International journal

    Masato Ohsawa, Kouichi Tamura, Hiromichi Wakui, Akinobu Maeda, Toru Dejima, Tomohiko Kanaoka, Kengo Azushima, Kazushi Uneda, Yuko Tsurumi-Ikeya, Ryu Kobayashi, Miyuki Matsuda, Shinichi Uchida, Yoshiyuki Toya, Hiroyuki Kobori, Akira Nishiyama, Akio Yamashita, Yoshihiro Ishikawa, Satoshi Umemura

    KIDNEY INTERNATIONAL   86 ( 3 )   570 - 581   2014.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/ki.2014.95

    Web of Science

    PubMed

    researchmap

  • Fetal programming by high-sucrose diet during pregnancy affects the vascular angiotensin II receptor-PKC-L-type Ca2+ channels (Ca(v)1.2) axis to enhance pressor responses Reviewed International journal

    Kouichi Tamura, Koji Ohki, Ryu Kobayashi, Kazushi Uneda, Kengo Azushima, Masato Ohsawa, Hiromichi Wakui, Satoshi Umemura

    HYPERTENSION RESEARCH   37 ( 9 )   796 - 798   2014.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/hr.2014.105

    Web of Science

    PubMed

    researchmap

  • Effects of Ang II Receptor Blocker Irbesartan on Adipose Tissue Function in Mice with Metabolic Disorders Reviewed International journal

    Akinobu Maeda, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Kengo Azushima, Kazushi Uneda, Ryu Kobayashi, Yuko Tsurumi-Ikeya, Tomohiko Kanaoka, Toru Dejima, Koji Ohki, Sona Haku, Akio Yamashita, Satoshi Umemura

    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES   11 ( 6 )   646 - 651   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.7150/ijms.8577

    Web of Science

    PubMed

    researchmap

  • Effects of the Angiotensin Receptor Blocker Olmesartan on Adipocyte Hypertrophy and Function in Mice with Metabolic Disorders Reviewed International journal

    Akinobu Maeda, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Kengo Azushima, Kazushi Uneda, Tomohiko Kanaoka, Ryu Kobayashi, Kohji Ohki, Miyuki Matsuda, Yuko Tsurumi-Ikeya, Akio Yamashita, Yasuo Tokita, Satoshi Umemura

    BIOMED RESEARCH INTERNATIONAL   2014   946492 - 946492   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1155/2014/946492

    Web of Science

    PubMed

    researchmap

  • Effects of Single Pill-Based Combination Therapy of Amlodipine and Atorvastatin on Within-Visit Blood Pressure Variability and Parameters of Renal and Vascular Function in Hypertensive Patients with Chronic Kidney Disease Reviewed International journal

    Kengo Azushima, Kazushi Uneda, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Ryu Kobayashi, Toru Dejima, Tomohiko Kanaoka, Akinobu Maeda, Yoshiyuki Toya, Satoshi Umemura

    BIOMED RESEARCH INTERNATIONAL   2014   437087 - 437087   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1155/2014/437087

    Web of Science

    PubMed

    researchmap

  • Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension Reviewed International journal

    Hiromichi Wakui, Toru Dejima, Kouichi Tamura, Kazushi Uneda, Koichi Azuma, Akinobu Maeda, Masato Ohsawa, Tomohiko Kanaoka, Kengo Azushima, Ryu Kobayashi, Miyuki Matsuda, Akio Yamashita, Satoshi Umemura

    Cardiovascular Research   100 ( 3 )   511 - 519   2013.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/cvr/cvt225

    Scopus

    PubMed

    researchmap

  • Bofu-Tsu-Shosan, an Oriental Herbal Medicine, Exerts a Combinatorial Favorable Metabolic Modulation Including Antihypertensive Effect on a Mouse Model of Human Metabolic Disorders with Visceral Obesity Reviewed International journal

    Kengo Azushima, Kouichi Tamura, Hiromichi Wakui, Akinobu Maeda, Masato Ohsawa, Kazushi Uneda, Ryu Kobayashi, Tomohiko Kanaoka, Toru Dejima, Tetsuya Fujikawa, Akio Yamashita, Yoshiyuki Toya, Satoshi Umemura

    PLOS ONE   8 ( 10 )   e75560   2013.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1371/journal.pone.0075560

    Web of Science

    PubMed

    researchmap

  • Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease Reviewed International journal

    Masato Ohsawa, Kouichi Tamura, Tomohiko Kanaoka, Hiromichi Wakui, Akinobu Maeda, Toru Dejima, Kengo Azushima, Kazushi Uneda, Ryu Kobayashi, Yuko Tsurumi-Ikeya, Yoshiyuki Toya, Tetsuya Fujikawa, Satoshi Umemura

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   14 ( 8 )   15361 - 15375   2013.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3390/ijms140815361

    Web of Science

    PubMed

    researchmap

  • L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease Reviewed International journal

    Tomohiko Kanaoka, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Kengo Azushima, Kazushi Uneda, Ryu Kobayashi, Tetsuya Fujikawa, Yuko Tsurumi-Ikeya, Akinobu Maeda, Mai Yanagi, Yoshiyuki Toya, Satoshi Umemura

    International Journal of Molecular Sciences   14 ( 8 )   16866 - 16881   2013

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3390/ijms140816866

    Scopus

    PubMed

    researchmap

  • Rectal carcinoma with metachronous metastasis to the extrahepatic bile duct without liver tumor Reviewed

    Noritoshi Kobayashi, Ryu Kobayashi, Shingo Kato, Seitaro Watanabe, Takashi Uchiyama, Takeshi Shimamura, Kensuke Kubota, Shin Maeda, Atsushi Nakajima, Yasushi Ichikawa, Hisashi Oshiro, Itaru Endo

    Clinical Journal of Gastroenterology   4 ( 4 )   278 - 282   2011.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12328-011-0240-y

    Scopus

    PubMed

    researchmap

  • [Prediction of gemcitabine treatment discontinuation based on platelet count before first administration].

    Ryoo Taniguchi, Akira Tokutome, Jun Matsunami, Syuuji Azuma, Miki Katsuragawa, Riki Hirata, Yuki Sato, Ryu Kobayashi, Yoshihiro Hashimoto, Kouji Meguro, Akio Shibanami, Keiya Okamura, Hiroyuki Miyakawa, Ryoji Tsumaki

    Gan to kagaku ryoho. Cancer & chemotherapy   37 ( 11 )   2105 - 8   2010.11

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    Decrease in white blood cell (WBC), neutrophil or platelet (PLT) count due to treatment with gemcitabine (GEM) is a dose-limited factor (DLF). Even for cases that satisfy the standard criteria for initiation of GEM therapy, the scheduled therapy is reportedly occasionally discontinued because of decreased PLT or WBC count. Here, a retrospective study was made to predict the factor causing discontinuation of GEM treatment before its first administration. The results showed that PLT count immediately before the first administration was significantly less in the unfinished administration group than in the finished group. It was also demonstrated that a PLT count less than 16×10/4 mL before the first administration of GEM was the significant risk factor leading to discontinuation of GEM treatment. Thus, it was suggested that this result would be available as the dose reduction standard to determine the first dose of GEM treatment.

    PubMed

    researchmap

  • [Investigation of factors associated with time change in breath alcohol concentration after paclitaxel administration].

    Ryoo Taniguchi, Norika Henmi, Riki Hirata, Tomohiro Tada, Yuki Sato, Fujiko Kamada, Miki Katsuragawa, Jun Matsunami, Ryu Kobayashi, Yoshihiro Hashimoto, Akio Shibanami, Ryoji Tsumaki

    Gan to kagaku ryoho. Cancer & chemotherapy   37 ( 7 )   1313 - 6   2010.7

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    Paclitaxel (PTX) injection is presently used for various types of cancer therapy. Because PTX is an insoluble medicine, alcohol is included. Therefore, after PTX administration, the breath alcohol concentration (BAC) detected is reported. We measured BAC after PTX administration and conducted an investigation into change over time. We also investigated factors associated with BAC. As a result, the BAC rate of detection just after the PTX administration was 52%. BAC was confirmed 3 hours after the administration. Therefore, sufficient rest periods were necessary after PTX administration and the need to avoid driving was proved. From comparison of the BAC detected and undetected groups, no significant sex differences were found in the BAC detected group in age, dosage, or body surface area. However, about a dosage per the time, many other things were significant in the BAC detected group in terms of dosage per time. From these results, it was suggested that the BAC detection rate rose with the dosage per time. However, one cannot predict BAC detection by the usual medical examination. Thus, when receiving PTX treatment on an outpatient basis, the patient should be warned not to drive to and from the clinic.

    PubMed

    researchmap

▼display all

MISC

  • On-going study to investigate the effects of receptor-binding molecule ATRAP on kidney tubule function and tissue pathology

    大用凌太郎, 塚本俊一郎, 大上尚仁, 小林竜, 金口翔, 小豆島健護, 金岡知彦, 涌井広道, 田村功一

    日本高血圧学会総会プログラム・抄録集(CD-ROM)   45th   2023

    　More details

  • 免疫チェックポイント阻害薬投与後に急性尿細管間質性腎炎および抗GBM抗体型糸球体腎炎を呈した1例

    石賀浩平, 小林竜, 金岡知彦, 藤井誠志, 涌井広道, 戸谷義幸, 田村功一

    日本腎臓学会誌(Web)   65 ( 6-E )   2023

    　More details

  • 経皮的腎生検困難な症例に対しガリウムシンチグラフィによりIgG4関連間質性腎炎と診断し治療開始できた一例

    福岡昭宏, 小豆島健護, 加藤実玖, 吉村汐莉, 浦手進吾, 石賀浩平, 金口翔, 小林竜, 金岡知彦, 涌井広道, 戸谷義幸, 田村功一

    日本腎臓学会誌(Web)   64 ( 6-E )   2022

    　More details

  • 5/6腎摘CKDモデルマウスを用いた高蛋白食負荷が腎障害に及ぼす影響についての検討

    田中翔平, 涌井広道, 大上尚仁, 塚本俊一郎, 浦手進吾, 小林竜, 小豆島健護, 田村功一

    日本腎臓学会誌(Web)   64 ( 3 )   2022

    　More details

  • 腎臓病に対する新しい治療ターゲット 糖尿病性腎臓病合併高血圧のトピックス

    涌井 広道, 浦手 進吾, 小林 竜, 金岡 知彦, 田村 功一

    Anti-aging Science   11 ( 1 )   47 - 47   2019.12

    　More details

    Language：Japanese   Publisher：(株)メディカルレビュー社  

    researchmap

  • 腎近位尿細管AT1受容体結合因子がアンジオテンシン依存性高血圧に及ぼす影響(Effects of AT1 Receptor-Associated Protein in Renal Proximal Tubules on Angiotensin II-Mediated Hypertension)

    金口 翔, 涌井 広道, 小豆島 健護, 春原 浩太郎, 高口 知之, 大城 光二, 畝田 一司, 白 善雅, 山地 孝拡, 山田 貴之, 小林 竜, 石上 友章, 山下 暁朗, 藤川 哲也, 田村 功一

    日本高血圧学会総会プログラム・抄録集   42回   200 - 200   2019.10

    　More details

    Language：English   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 関節リウマチ患者に発症したステロイド抵抗性ネフローゼ症候群の一例

    藏口 裕美, 小林 竜, 花岡 正哲, 堀米 麻里, 春原 須美玲, 金口 翔, 金岡 智彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   61 ( 6 )   873 - 873   2019.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 臓器合併症があり診断に難渋した原発性アルドステロン症の1例

    平塚 梨奈, 堀米 麻里, 角田 剛一朗, 植田 瑛子, 花岡 正哲, 岩野 剛久, 金口 翔, 小林 竜, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   61 ( 6 )   718 - 718   2019.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 当院における入院患者データベース作成について

    金岡 知彦, 堀米 麻里, 平塚 梨奈, 角田 剛一朗, 花岡 正哲, 岩野 剛久, 植田 瑛子, 金口 翔, 小林 竜, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   61 ( 6 )   775 - 775   2019.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 迅速ACTH負荷試験により診断に至った原発性アルドステロン症の1例

    竹之内 陽子, 大城 光二, 大上 尚仁, 平塚 梨奈, 春原 須美玲, 花岡 正哲, 小林 竜, 畝田 一司, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   8回   179 - 179   2019.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 横浜市立大学附属病院腎臓・高血圧内科における入院患者データベース構築の取り組み

    金岡 知彦, 大上 尚仁, 平塚 梨奈, 春原 須美玲, 角田 剛一朗, 花岡 正哲, 金口 翔, 大城 光二, 畝田 一司, 小林 竜, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   8回   175 - 175   2019.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 迅速ACTH負荷試験により診断に至った原発性アルドステロン症の1例

    竹之内 陽子, 大城 光二, 大上 尚仁, 平塚 梨奈, 春原 須美玲, 花岡 正哲, 小林 竜, 畝田 一司, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   8回   179 - 179   2019.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • めまいを有する維持血液透析患者に腹膜透析を併用した1例

    花岡 正哲, 小林 竜, 春原 須美玲, 大上 尚仁, 平塚 梨奈, 大城 光二, 畝田 一司, 金岡 知彦, 涌井 広道, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   52 ( Suppl.1 )   797 - 797   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 新規血管新生因子LRG1の2型糖尿病性腎症における意義の検討

    白 善雅, 涌井 広道, 浦手 進吾, 山地 孝拡, 金口 翔, 小林 竜, 田村 功一

    日本腎臓学会誌   61 ( 3 )   359 - 359   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 漢方薬「六君子湯」による腎保護効果の検討

    畝田 一司, 小豆島 健護, 涌井 広道, 大城 光二, 春原 浩太郎, 小林 竜, 金口 翔, 山地 孝拡, 浦手 進吾, 田村 功一

    日本腎臓学会誌   61 ( 3 )   404 - 404   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 新規血管新生因子LRG1の2型糖尿病性腎症における意義の検討

    白 善雅, 涌井 広道, 浦手 進吾, 山地 孝拡, 金口 翔, 小林 竜, 田村 功一

    日本腎臓学会誌   61 ( 3 )   359 - 359   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 漢方薬「六君子湯」による腎保護効果の検討

    畝田 一司, 小豆島 健護, 涌井 広道, 大城 光二, 春原 浩太郎, 小林 竜, 金口 翔, 山地 孝拡, 浦手 進吾, 田村 功一

    日本腎臓学会誌   61 ( 3 )   404 - 404   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 横浜市立大学附属病院腎臓・高血圧内科における入院患者データベース構築の取り組み

    金岡 知彦, 大上 尚仁, 平塚 梨奈, 春原 須美玲, 角田 剛一朗, 花岡 正哲, 金口 翔, 大城 光二, 畝田 一司, 小林 竜, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   8回   175 - 175   2019.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • AT1受容体結合因子ATRAPの白血球における発現と機能に関する検討

    春原 浩太郎, 涌井 広道, 畝田 一司, 小林 竜, 白 善雅, 大城 光二, 金口 翔, 山田 貴之, 山地 孝拡, 田村 功一

    日本内分泌学会雑誌   94 ( 4 )   1554 - 1554   2018.12

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • AT1受容体結合因子ATRAPの白血球における発現と機能に関する検討

    春原 浩太郎, 涌井 広道, 畝田 一司, 小林 竜, 白 善雅, 大城 光二, 金口 翔, 山田 貴之, 山地 孝拡, 田村 功一

    日本内分泌学会雑誌   94 ( 4 )   1554 - 1554   2018.12

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • 慢性腎臓病CKDと抗加齢医学 受容体結合性機能制御蛋白と腎性老化

    田村 功一, 涌井 広道, 山地 孝拡, 畝田 一司, 小林 竜, 大城 光二, 金口 翔, 山田 貴之, 浦手 進吾, 山下 暁朗

    Anti-aging Science   10 ( 1 )   45 - 45   2018.12

    　More details

    Language：Japanese   Publisher：(株)メディカルレビュー社  

    researchmap

  • 六君子湯による腎保護効果の検討

    中村 朗子, 涌井 広道, 畝田 一司, 小林 竜, 大城 光二, 金岡 知彦, 春原 浩太郎, 金口 翔, 山地 孝拡, 山田 貴之, 上村 大輔, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   41回   PB06 - 06   2018.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 和漢薬の有効性のエビデンス:最新の臨床試験から 肥満高血圧に対する防風通聖散の効果に関する基礎的・臨床的研究

    田村 功一, 小豆島 健護, 畝田 一司, 小林 竜, 大城 光二, 藤川 哲也, 涌井 広道

    和漢医薬学会学術大会要旨集   35回   74 - 74   2018.9

    　More details

    Language：Japanese   Publisher：(一社)和漢医薬学会  

    researchmap

  • 和漢薬の有効性のエビデンス:最新の臨床試験から 肥満高血圧に対する防風通聖散の効果に関する基礎的・臨床的研究

    田村 功一, 小豆島 健護, 畝田 一司, 小林 竜, 大城 光二, 藤川 哲也, 涌井 広道

    和漢医薬学会学術大会要旨集   35回   74 - 74   2018.9

    　More details

    Language：Japanese   Publisher：(一社)和漢医薬学会  

    researchmap

  • 中枢性血圧調節におけるATRAPの機能的意義

    金口 翔, 涌井 広道, 山田 貴之, 山地 孝拡, 春原 浩太郎, 大城 光二, 白 善雅, 小林 竜, 畝田 一司, 浦手 進吾, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   41回   PB04 - 03   2018.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 頻回再発型MCNSに対しプレドニゾロンとリツキシマブが併用された患者にニューモシスチス肺炎を認めた症例

    大上 尚仁, 小林 竜, 春原 須美玲, 平塚 梨奈, 花岡 正哲, 大城 光二, 畝田 一司, 金岡 知彦, 橋本 達夫, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   60 ( 6 )   872 - 872   2018.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • インフルエンザを契機に再燃したANCA関連腎炎の一例

    春原 須美玲, 小林 竜, 大上 尚仁, 平塚 梨奈, 花岡 正哲, 大城 光二, 畝田 一司, 金岡 知彦, 涌井 広道, 戸谷 義幸, 大橋 健一, 田村 功一

    日本腎臓学会誌   60 ( 6 )   874 - 874   2018.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • インフルエンザを契機に再燃したANCA関連腎炎の一例

    春原 須美玲, 小林 竜, 大上 尚仁, 平塚 梨奈, 花岡 正哲, 大城 光二, 畝田 一司, 金岡 知彦, 涌井 広道, 戸谷 義幸, 大橋 健一, 田村 功一

    日本腎臓学会誌   60 ( 6 )   874 - 874   2018.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 認知症を有する高齢末期腎不全患者に対し透析療法見合わせを検討するも導入にて良好な経過をたどった一例

    佐々木 朱夏, 小林 竜, 大上 尚仁, 毛利 史將, 谷津 圭介, 涌井 広道, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   51 ( Suppl.1 )   866 - 866   2018.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 慢性腎臓病患者における降圧目標

    田村 功一, 涌井 広道, 畝田 一司, 小林 竜, 金岡 知彦, 大城 光二, 大澤 正人, 平和 伸仁, 戸谷 義幸, 常田 康夫

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   7回   114 - 114   2018.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • オープンダイアローグを念頭に置いた、自己管理不良の血液透析患者との対話の試み

    矢花 眞知子, 涌井 広道, 大上 尚仁, 春原 須美玲, 毛利 史将, 川井 有紀, 植田 瑛子, 小林 竜, 池谷 裕子, 橋本 達夫, 坂 早苗, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   51 ( Suppl.1 )   715 - 715   2018.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 認知症を有する高齢末期腎不全患者に対し透析療法見合わせを検討するも導入にて良好な経過をたどった一例

    佐々木 朱夏, 小林 竜, 大上 尚仁, 毛利 史將, 谷津 圭介, 涌井 広道, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   51 ( Suppl.1 )   866 - 866   2018.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • オープンダイアローグを念頭に置いた、自己管理不良の血液透析患者との対話の試み

    矢花 眞知子, 涌井 広道, 大上 尚仁, 春原 須美玲, 毛利 史将, 川井 有紀, 植田 瑛子, 小林 竜, 池谷 裕子, 橋本 達夫, 坂 早苗, 戸谷 義幸, 田村 功一

    日本透析医学会雑誌   51 ( Suppl.1 )   715 - 715   2018.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 中枢神経系ATRAPによる血圧制御

    金口 翔, 涌井 広道, 山田 貴之, 山地 孝拡, 春原 浩太郎, 大城 光二, 白 善雅, 小林 竜, 畝田 一司, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   60 ( 3 )   465 - 465   2018.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 【高齢者医療ハンドブック-高齢者医療におけるダイバーシティへの対応】(第VII章)高齢者の慢性疾患管理法 慢性腎臓病

    田村 功一, 大城 光二, 小林 竜, 畝田 一司, 涌井 広道

    内科   121 ( 4 )   867 - 873   2018.4

    　More details

    Language：Japanese   Publisher：(株)南江堂  

    DOI： 10.15106/j_naika121_867

    researchmap

  • 保存期CKD患者に対するエポエチンベータペゴルとダルベポエチルアルファの血圧に関する比較検討

    大城 光二, 涌井 広道, 小豆島 健護, 畝田 一司, 小林 竜, 白 善雅, 春原 浩太郎, 金口 翔, 山田 貴之, 山地 孝拡, 藤川 哲也, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   60 ( 3 )   425 - 425   2018.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 中枢神経系ATRAPによる血圧制御

    金口 翔, 涌井 広道, 山田 貴之, 山地 孝拡, 春原 浩太郎, 大城 光二, 白 善雅, 小林 竜, 畝田 一司, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   60 ( 3 )   465 - 465   2018.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 保存期CKD患者に対するエポエチンベータペゴルとダルベポエチルアルファの血圧に関する比較検討

    大城 光二, 涌井 広道, 小豆島 健護, 畝田 一司, 小林 竜, 白 善雅, 春原 浩太郎, 金口 翔, 山田 貴之, 山地 孝拡, 藤川 哲也, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   60 ( 3 )   425 - 425   2018.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • ネフローゼ症候群を伴うIgA腎症の一例

    大上 尚仁, 小林 竜, 春原 須美玲, 毛利 史將, 川井 有紀, 畝田 一司, 山内 淳司, 谷津 圭介, 涌井 広道, 戸谷 義幸, 田村 功一, 三宅 暁夫, 大橋 健一, 城 謙輔, 山口 裕

    腎炎症例研究   34   221 - 238   2018.2

    　More details

    Language：Japanese   Publisher：日本ベーリンガーインゲルハイム(株)  

    researchmap

  • 原因不明の低アルブミン血症に対してGaシンチグラフィーが診断に有用であった1例

    大上 尚仁, 谷津 圭介, 毛利 史將, 小林 竜, 涌井 広道, 戸谷 義幸, 田村 功一

    日本内科学会雑誌   107 ( Suppl. )   190 - 190   2018.2

    　More details

    Language：Japanese   Publisher：(一社)日本内科学会  

    researchmap

  • ネフローゼ症候群を伴うIgA腎症の一例

    大上 尚仁, 小林 竜, 春原 須美玲, 毛利 史將, 川井 有紀, 畝田 一司, 山内 淳司, 谷津 圭介, 涌井 広道, 戸谷 義幸, 田村 功一, 三宅 暁夫, 大橋 健一, 城 謙輔, 山口 裕

    腎炎症例研究   34   221 - 238   2018.2

    　More details

    Language：Japanese   Publisher：日本ベーリンガーインゲルハイム(株)  

    researchmap

  • 慢性腎臓病における高血圧発症 腎ATRAPの決定的な役割

    小林 竜, 涌井 広道, 田村 功一

    日本腎臓学会誌   59 ( 8 )   1225 - 1228   2017.12

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 糖脂質代謝障害における1型アンジオテンシンII受容体結合蛋白ATRAPの機能的意義

    大城 光二, 涌井 広道, 小豆島 健護, 畝田 一司, 小林 竜, 春原 浩太郎, 岸尾 望, 中島 淳, 山下 暁朗, 田村 功一

    日本内分泌学会雑誌   93 ( 4 )   1383 - 1383   2017.12

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • 糖脂質代謝障害における1型アンジオテンシンII受容体結合蛋白ATRAPの機能的意義

    大城 光二, 涌井 広道, 小豆島 健護, 畝田 一司, 小林 竜, 春原 浩太郎, 岸尾 望, 中島 淳, 山下 暁朗, 田村 功一

    日本内分泌学会雑誌   93 ( 4 )   1383 - 1383   2017.12

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • 近位尿細管特異的ATRAPノックアウトマウスの作製とアンジオテンシン依存性高血圧への影響

    高口 知之, 金口 翔, 山田 貴之, 山地 孝拡, 春原 浩太朗, 大城 光二, 白 善雅, 小林 竜, 畝田 一司, 小豆島 健護, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   425 - 425   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アディポネクチンプロモーター制御下1型アンジオテンシンII受容体結合因子(ATRAP)高発現マウスにおける慢性アンジオテンシンII刺激によるインスリン抵抗性の検討

    大城 光二, 涌井 広道, 大澤 正人, 小豆島 健護, 白 善雅, 畝田 一司, 小林 竜, 春原 浩太郎, 金口 翔, 山田 貴之, 山地 孝拡, 岸尾 望, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   357 - 357   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 原発性アルドステロン症における24時間自由行動下血圧測定を含めた臨床的特徴の検討

    春原 須美玲, 小豆島 健護, 大上 尚仁, 毛利 史將, 川井 有紀, 畝田 一司, 小林 竜, 山内 淳司, 谷津 圭介, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   397 - 397   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 局所RAAS活性化はどの様にして高血圧を引き起こすのか? 慢性腎臓病での高血圧における尿細管ATRAPの役割

    涌井 広道, 小林 竜, 大澤 正人, 小豆島 健護, 畝田 一司, 大城 光二, 春原 浩太郎, 金口 翔, 山地 孝拡, 山田 貴之, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   297 - 297   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 六君子湯のグレリン活性化作用に着目した腎保護効果の検討

    高山 純佳, 鈴木 将太, 中野 雅友樹, 山田 貴之, 山地 孝拡, 金口 翔, 大城 光二, 春原 浩太郎, 小林 竜, 畝田 一司, 小豆島 健護, 橋本 達夫, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   431 - 431   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン依存性高血圧における中枢神経系でのATRAPの病態生理学的意義

    金口 翔, 山田 貴之, 山地 孝拡, 春原 浩太朗, 大城 光二, 白 善雅, 小林 竜, 畝田 一司, 小豆島 健護, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   426 - 426   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 近位尿細管特異的ATRAPノックアウトマウスの作製とアンジオテンシン依存性高血圧への影響

    高口 知之, 金口 翔, 山田 貴之, 山地 孝拡, 春原 浩太朗, 大城 光二, 白 善雅, 小林 竜, 畝田 一司, 小豆島 健護, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   425 - 425   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン依存性高血圧における中枢神経系でのATRAPの病態生理学的意義

    金口 翔, 山田 貴之, 山地 孝拡, 春原 浩太朗, 大城 光二, 白 善雅, 小林 竜, 畝田 一司, 小豆島 健護, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   426 - 426   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アディポネクチンプロモーター制御下1型アンジオテンシンII受容体結合因子(ATRAP)高発現マウスにおける慢性アンジオテンシンII刺激によるインスリン抵抗性の検討

    大城 光二, 涌井 広道, 大澤 正人, 小豆島 健護, 白 善雅, 畝田 一司, 小林 竜, 春原 浩太郎, 金口 翔, 山田 貴之, 山地 孝拡, 岸尾 望, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   357 - 357   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 六君子湯のグレリン活性化作用に着目した腎保護効果の検討

    高山 純佳, 鈴木 将太, 中野 雅友樹, 山田 貴之, 山地 孝拡, 金口 翔, 大城 光二, 春原 浩太郎, 小林 竜, 畝田 一司, 小豆島 健護, 橋本 達夫, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   431 - 431   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 局所RAAS活性化はどの様にして高血圧を引き起こすのか? 慢性腎臓病での高血圧における尿細管ATRAPの役割

    涌井 広道, 小林 竜, 大澤 正人, 小豆島 健護, 畝田 一司, 大城 光二, 春原 浩太郎, 金口 翔, 山地 孝拡, 山田 貴之, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   297 - 297   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 原発性アルドステロン症における24時間自由行動下血圧測定を含めた臨床的特徴の検討

    春原 須美玲, 小豆島 健護, 大上 尚仁, 毛利 史將, 川井 有紀, 畝田 一司, 小林 竜, 山内 淳司, 谷津 圭介, 涌井 広道, 戸谷 義幸, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   397 - 397   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 腰椎圧迫骨折に対するデノスマブ投与により急激な低Ca血症を認めた一例

    鈴木 華織, 畝田 一司, 山崎 孝明, 大上 尚仁, 春原 須美玲, 毛利 史將, 川井 有紀, 小林 竜, 山内 淳司, 谷津 圭介, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   59 ( 6 )   920 - 920   2017.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 維持透析中の患者における尿路結石による腎盂腎炎

    大上 尚仁, 小林 竜, 田村 功一, 戸谷 義幸, 涌井 広道, 谷津 圭介, 山内 淳司, 畝田 一司, 川井 有紀, 毛利 史将, 春原 須美玲

    日本腎臓学会誌   59 ( 6 )   719 - 719   2017.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 腎生検によりループス腎炎と鑑別し得たMPO-ANCA関連腎炎の一例

    吉村 勇人, 畝田 一司, 春原 須美玲, 川井 有紀, 松本 賛良, 中森 悠, 小林 竜, 山内 淳司, 谷津 圭介, 橋本 達夫, 涌井 広道, 戸谷 義幸, 田村 功一

    日本腎臓学会誌   59 ( 6 )   744 - 744   2017.9

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 【降圧をめぐる最新エビデンスから腎・高血圧診療を考える】 腎予後の改善に厳格降圧は無効か SPRINT研究から

    田村 功一, 小林 竜, 畝田 一司, 春原 浩太郎, 涌井 広道

    腎・高血圧の最新治療   6 ( 3 )   126 - 134   2017.7

    　More details

  • 降圧療法に難渋した抗結核薬加療中の悪性高血圧の一例

    渡部 衛, 小林 竜, 谷津 圭介, 涌井 広道, 橋本 達夫, 山内 淳司, 松本 賛良, 春原 須美玲, 戸谷 義幸, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   6回   145 - 145   2017.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 降圧療法の完成度を上げる Fine-tuning of blood pressure control 血圧変動と腎疾患 慢性腎臓病に克つための血圧管理

    田村 功一, 小豆島 健護, 畝田 一司, 小林 竜, 涌井 広道

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   6回   101 - 101   2017.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ATRAPはアンジオテンシンII1型受容体非依存性の機序により腎老化および寿命を制御する

    畝田 一司, 涌井 広道, 前田 晃延, 小豆島 健護, 白 善雅, 小林 竜, 大城 光二, 春原 浩太郎, 金口 翔, 山下 暁朗, 田村 功一

    日本腎臓学会誌   59 ( 3 )   354 - 354   2017.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • ストレプトゾトシン誘発糖尿病腎症モデルマウスにおけるAT1受容体直接結合因子ATRAPの意義

    春原 浩太郎, 涌井 広道, 小豆島 健護, 小林 竜, 大城 光二, 金口 翔, 坪井 伸夫, 横尾 隆, 田村 功一

    日本腎臓学会誌   59 ( 3 )   253 - 253   2017.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • アンジオテンシンII1型受容体直接結合因子ATRAPは慢性腎臓病における高血圧発症に決定的な役割を示す

    小林 竜, 涌井 広道, 小豆島 健護, 畝田 一司, 白 善雅, 大城 光二, 春原 浩太郎, 金口 翔, 梅村 敏, 田村 功一

    日本腎臓学会誌   59 ( 3 )   263 - 263   2017.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Cre/loxPシステムによる1型アンジオテンシンII受容体結合因子(ATRAP)の組織特異的発現抑制マウス作成の試み

    大城 光二, 涌井 広道, 小豆島 健護, 白 善雅, 畝田 一司, 小林 竜, 春原 浩太郎, 金口 翔, 松田 美由紀, 田村 功一

    日本内分泌学会雑誌   92 ( 3 )   902 - 902   2017.1

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • 脂肪組織における1型アンジオテンシンII受容体結合因子(ATRAP/Agtrap)の機能的意義の検討

    大城 光二, 涌井 広道, 小豆島 健護, 白 善雅, 畝田 一司, 小林 竜, 春原 浩太郎, 金口 翔, 大澤 正人, 前田 晃延, 梅村 敏, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   318 - 318   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • C57BL/6野生型マウスにおけるアンジオテンシンII刺激によるインスリン抵抗性の検討および1型アンジオテンシンII受容体結合因子(ATRAP)の脂肪組織特異的高発現マウスの作成

    岸尾 望, 涌井 広道, 大澤 正人, 小豆島 健護, 白 善雅, 畝田 一司, 小林 竜, 大城 光二, 金口 翔, 前田 晃延, 梅村 敏, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   337 - 337   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 脂肪組織におけるアンジオテンシン受容体結合因子(ATRAP/Agtrap)の高発現は食餌性肥満およびインスリン抵抗性の増悪を抑制する

    小豆島 健護, 涌井 広道, 畝田 一司, 白 善雅, 小林 竜, 大城 光二, 春原 浩太郎, 金口 翔, 戸谷 義幸, 山下 暁郎, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   317 - 317   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 脂肪組織におけるアンジオテンシン受容体結合因子(ATRAP/Agtrap)の高発現は食餌性肥満およびインスリン抵抗性の増悪を抑制する

    小豆島 健護, 涌井 広道, 畝田 一司, 白 善雅, 小林 竜, 大城 光二, 春原 浩太郎, 金口 翔, 戸谷 義幸, 山下 暁郎, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   317 - 317   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 脂肪組織における1型アンジオテンシンII受容体結合因子(ATRAP/Agtrap)の機能的意義の検討

    大城 光二, 涌井 広道, 小豆島 健護, 白 善雅, 畝田 一司, 小林 竜, 春原 浩太郎, 金口 翔, 大澤 正人, 前田 晃延, 梅村 敏, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   318 - 318   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン受容体結合因子ATRAPが加齢に伴う臓器障害に及ぼす影響についての検討

    畝田 一司, 涌井 広道, 前田 晃延, 小豆島 健護, 白 善雅, 小林 竜, 大城 光二, 春原 浩太郎, 金口 翔, 戸谷 義幸, 跡部 好敏, 山下 暁朗, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   340 - 340   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 中枢神経におけるATRAP/AT1R発現比の低下は本態性高血圧の発症・進展にかかわる

    金口 翔, 涌井 広道, 小豆島 健護, 畝田 一司, 白 善雅, 小林 竜, 春原 浩太朗, 大城 光二, 梅村 敏, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   341 - 341   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • C57BL/6野生型マウスにおけるアンジオテンシンII刺激によるインスリン抵抗性の検討および1型アンジオテンシンII受容体結合因子(ATRAP)の脂肪組織特異的高発現マウスの作成

    岸尾 望, 涌井 広道, 大澤 正人, 小豆島 健護, 白 善雅, 畝田 一司, 小林 竜, 大城 光二, 金口 翔, 前田 晃延, 梅村 敏, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   337 - 337   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン受容体結合因子ATRAPが加齢に伴う臓器障害に及ぼす影響についての検討

    畝田 一司, 涌井 広道, 前田 晃延, 小豆島 健護, 白 善雅, 小林 竜, 大城 光二, 春原 浩太郎, 金口 翔, 戸谷 義幸, 跡部 好敏, 山下 暁朗, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   340 - 340   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 中枢神経におけるATRAP/AT1R発現比の低下は本態性高血圧の発症・進展にかかわる

    金口 翔, 涌井 広道, 小豆島 健護, 畝田 一司, 白 善雅, 小林 竜, 春原 浩太朗, 大城 光二, 梅村 敏, 田村 功一

    日本高血圧学会総会プログラム・抄録集   39回   341 - 341   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • AT1受容体直接結合因子ATRAPのヒト末梢血白血球における遺伝子発現と臨床指標との関連

    春原 浩太郎, 田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 白 善雅, 小林 竜, 大城 光二, 金口 翔, 松田 みゆき, 山下 暁朗, 坪井 伸夫, 横尾 隆, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   39回   374 - 374   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    J-GLOBAL

    researchmap

  • AT1受容体結合因子ATRAPの欠損は、慢性腎臓病下で高血圧を悪化させる

    小林 竜, 田村 功一, 涌井 広道, 小豆島 健護, 白 善雅, 畝田 一司, 春原 浩太郎, 大城 光二, 金口 翔, 梅村 敏

    日本腎臓学会誌   58 ( 3 )   367 - 367   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • アンジオテンシンII受容体結合因子ATRAPの欠損は加齢に伴う腎障害を増悪させる

    畝田 一司, 田村 功一, 涌井 広道, 前田 晃延, 小豆島 健護, 白 善雅, 小林 竜, 大城 光二, 金口 翔, 跡部 好敏, 山下 暁朗, 梅村 敏

    日本腎臓学会誌   58 ( 3 )   260 - 260   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • AT1受容体直接結合因子ATRAPのヒト白血球における発現と臨床指標との関連

    春原 浩太郎, 田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 畝田 一司, 小林 竜, 大城 光二, 金口 翔, 坪井 伸夫, 横尾 隆, 梅村 敏

    日本腎臓学会誌   58 ( 3 )   317 - 317   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 【合剤による血圧管理】 CKD合併高血圧への合剤の適用法

    田村 功一, 小林 竜, 畝田 一司, 小豆島 健護

    血圧   23 ( 5 )   340 - 344   2016.5

    　More details

    Language：Japanese   Publisher：(株)先端医学社  

    researchmap

  • 【合剤による血圧管理】 CKD合併高血圧への合剤の適用法

    田村 功一, 小林 竜, 畝田 一司, 小豆島 健護

    血圧   23 ( 5 )   340 - 344   2016.5

    　More details

    Language：Japanese   Publisher：(株)先端医学社  

    researchmap

  • 保存期慢性腎臓病(CKD)患者における診察室内血圧変動性の意義

    小豆島 健護, 田村 功一, 涌井 広道, 大澤 正人, 畝田 一司, 白 善雅, 小林 竜, 大城 光二, 金口 翔, 春原 浩太郎, 藤川 哲也, 戸谷 義幸, 梅村 敏

    日本腎臓学会誌   58 ( 3 )   353 - 353   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Development of New Therapeutic Strategy by Receptor Binding Molecule-Mediated Regulation of Chronic Kidney Disease

    田村功一, 小林竜, 畝田一司, 小豆島健護, 大澤正人, 涌井広道

    ソルト・サイエンス研究財団助成研究報告集 2 医学 食品科学編   2014   59 - 72   2016.3

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 【急性腎障害、慢性腎臓病-その常識は正しいか?-】 保存期慢性腎臓病 その常識は正しいか? 厳格な血圧管理は患者予後を改善する(生命予後、心血管予後、腎予後、管理目標値)

    田村 功一, 畝田 一司, 小林 竜

    救急・集中治療   28 ( 3-4 )   189 - 198   2016.3

    　More details

    Language：Japanese   Publisher：(株)総合医学社  

    researchmap

  • 直接的レニン阻害薬およびアンジオテンシンII受容体拮抗薬がCKD合併高血圧患者の診察室血圧、自由行動下血圧へ与える効果に関する検討

    畝田 一司, 田村 功一, 涌井 広道, 小豆島 健護, 白 善雅, 小林 竜, 大城 光二, 春原 浩太郎, 金口 翔, 大澤 正人, 金岡 知彦, 前田 晃延, 藤川 哲也, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   38回   459 - 459   2015.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 慢性腎臓病合併高血圧に対するイルベサルタン/アムロジピン配合薬の家庭血圧、血圧変動性と血管機能に与える影響に関する検討

    小林 竜, 田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 白 善雅, 畝田 一司, 春原 浩太郎, 大城 光二, 金口 翔, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   38回   459 - 459   2015.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 慢性腎臓病(CKD)合併高血圧に対する血圧・脂質降下療法が超短期血圧変動に与える影響

    小豆島 健護, 田村 功一, 涌井 広道, 大澤 正人, 畝田 一司, 小林 竜, 大城 光二, 春原 浩太郎, 戸谷 義幸, 梅村 敏

    日本腎臓学会誌   57 ( 3 )   573 - 573   2015.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • マウス慢性腎臓病病態モデルにおけるAT1受容体結合因子ATRAP発現調節についての検討

    小林 竜, 田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 畝田 一司, 大城 光二, 出島 徹, 前田 晃延, 戸谷 義幸, 山下 暁朗, 田邉 克幸, 前島 洋平, 槇野 博史, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   401 - 401   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 高血圧診療の先進医療、先制医療、統合医療(miRNA、エピジェネティクス、免疫、ワクチン、漢方) 肥満合併高血圧に対する漢方薬を用いた統合医療の効果

    小豆島 健護, 田村 功一, 涌井 広道, 大澤 正人, 畝田 一司, 小林 竜, 大城 光二, 出島 徹, 前田 晃延, 白 善雅, 藤川 哲也, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   293 - 293   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • マウス尿細管でのATRAP発現増強が高塩分食負荷時の血圧に及ぼす影響についての検討

    畝田 一司, 田村 功一, 涌井 広道, 出島 徹, 大澤 正人, 小豆島 健護, 小林 竜, 大城 光二, 白 善雅, 金岡 知彦, 前田 晃延, 松田 みゆき, 戸谷 義幸, 山下 暁朗, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   324 - 324   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • レニン・アンジオテンシン・アルドステロン系の研究・臨床の最先端 受容体結合因子ATRAP/Agtrapを介した腎尿細管機能制御と血圧調節

    田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 畝田 一司, 小林 竜, 大城 光二, 松田 みゆき, 大友 優太, 山下 暁朗, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   241 - 241   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 腎線維化におけるAT1受容体結合因子ATRAPの発現調節についての検討

    大友 優太, 涌井 広道, 田村 功一, 大澤 正人, 小豆島 健護, 畝田 一司, 小林 竜, 大城 光二, 戸谷 義幸, 山下 暁朗, 田邊 克幸, 前島 洋平, 槇野 博史, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   337 - 337   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン受容体結合因子(ATRAP/Agtrap)の内臓脂肪型肥満 生活習慣病における病態生理学的意義についての検討

    大城 光二, 田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 畝田 一司, 小林 竜, 前田 晃延, 出島 徹, 松田 みゆき, 山下 暁朗, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   329 - 329   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン受容体結合因子ATRAP/Agtrapの血圧調節における病態生理学的意義について

    大澤 正人, 田村 功一, 涌井 広道, 小豆島 健護, 畝田 一司, 小林 竜, 大城 光二, 池谷 裕子, 金岡 知彦, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   333 - 333   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 慢性腎臓病合併高血圧に対するアムロジピン/アトルバスタチン配合錠を用いた厳格な血圧および脂質管理の及ぼす影響に関する検討

    小豆島 健護, 田村 功一, 畝田 一司, 涌井 広道, 大澤 正人, 小林 竜, 大城 光二, 出島 徹, 金岡 知彦, 前田 晃延, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   418 - 418   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • イルベサルタンは、脂肪組織におけるLeptin-炎症性サイトカインを抑制し、抗肥満作用を発揮する

    涌井 広道, 前田 晃延, 田村 功一, 大城 光二, 小林 竜, 畝田 一司, 小豆島 健護, 大澤 正人, 出島 徹, 増田 真一朗, 戸谷 義幸, 山下 暁朗, 矢花 眞知子, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   337 - 337   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 【最新臨床高血圧学-高血圧治療の最前線-】 高血圧の治療・管理 薬物治療 有用性と安全性 新規降圧薬 ネプリライシン阻害薬

    田村 功一, 小林 竜, 梅村 敏

    日本臨床   72 ( 増刊6 最新臨床高血圧学 )   379 - 385   2014.8

    　More details

    Language：Japanese   Publisher：(株)日本臨床社  

    researchmap

  • 【腹膜透析2014】 両側横隔膜交通症の一例

    小林 竜, 柳 麻衣, 吉浦 辰徳, 土屋 武弘, 佐野 厚, 深見 武史

    腎と透析   77 ( 別冊 腹膜透析2014 )   273 - 274   2014.8

    　More details

    Language：Japanese   Publisher：(株)東京医学社  

    54歳女。巣状分節状糸球体性硬化症による末期腎不全のため、CAPDカテーテル留置術をSMAP法で施行した。腹膜透析導入目的で入院した。出口部作製術を施行し、腹膜透析液の貯留を開始したところ、乾性咳嗽および右胸部圧迫感を自覚した。胸部X線で右胸水貯留を認め、99mTc-MAAシンチグラフィで右横隔膜交通症と診断した。交通部位同定法に色素注入法を用いて右胸腔鏡下横隔膜縫縮術を施行した。術後4日目から腹膜透析を開始した。胸水貯留のないことを確認し、軽快退院した。退院4ヵ月後、乾性咳嗽および左胸水貯留を認め、再入院した。99mTc-MAAシンチグラフィで左横隔膜交通症と診断した。腹膜透析継続を希望したため、左胸腔鏡下横隔膜縫縮術を施行した。術後5日目から腹膜透析を開始した。胸水貯留のないことを確認し、退院した。術後1年経過した現在、再発を認めず、腹膜透析を継続している。

    researchmap

  • 【JNC8を検証する】 慢性腎臓病(CKD)合併高血圧・糖尿病合併高血圧の管理

    田村 功一, 大城 光二, 小林 竜, 常田 康夫

    血圧   21 ( 8 )   686 - 690   2014.8

    　More details

    Language：Japanese   Publisher：(株)先端医学社  

    researchmap

  • ANGIOTENSIN RECEPTOR-BINDING PROTEIN ATRAP IN RENAL TUBULE IS AN IMPORTANT MODULATOR OF BLOOD PRESSURE UNDER PATHOLOGICAL STIMULATION

    Wakui Hiromichi, Tamura Kouichi, Ohsawa Masato, Kobayashi Ryu, Uneda Kazushi, Azushima Kengo, Toya Yoshiyuki, Umemura Satoshi

    NEPHROLOGY   19   106 - 106   2014.5

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 老化モデルマウスの腎臓におけるATRAPとKlothoの相関の可能性

    畝田 一司, 田村 功一, 涌井 広道, 大澤 正人, 小豆島 健護, 小林 竜, 戸谷 義幸, 山下 暁朗, 梅村 敏

    日本腎臓学会誌   56 ( 3 )   341 - 341   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 高ヘモグロビンの経過観察中にランソプラゾールが原因と考えられる汎血球減少を呈した血液透析患者の1例

    矢花 眞知子, 涌井 広道, 植田 瑛子, 鈴木 将太, 小林 竜, 吉田 伸一郎, 池谷 裕子, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   47 ( Suppl.1 )   590 - 590   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 【家庭血圧-これからの高血圧個別治療へ-】 慢性腎臓病合併高血圧

    田村 功一, 小林 竜, 畝田 一司

    カレントテラピー   32 ( 3 )   269 - 275   2014.3

    　More details

    Language：Japanese   Publisher：(株)ライフメディコム  

    researchmap

  • 長期間のアンジオテンシンII負荷は腎臓のKlothoとATRAP発現を低下させる

    畝田 一司, 田村 功一, 涌井 広道, 出島 徹, 大澤 正人, 小豆島 健護, 小林 竜, 白 善雅, 金岡 知彦, 前田 晃延, 戸谷 義幸, 山下 暁朗, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   350 - 350   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 受容体直接結合蛋白によるアンジオテンシンAT1受容体情報伝達系抑制システムの血圧調節および心血管系障害における病態生理学的意義について

    田村 功一, 涌井 広道, 出島 徹, 東 公一, 大澤 正人, 小豆島 健護, 畝田 一司, 小林 竜, 大城 光二, 前田 晃延, 金岡 知彦, 鶴見 裕子, 谷, 松田 みゆき, 梅村 敏

    血管   36 ( 3 )   103 - 111   2013.10

    　More details

    Language：Japanese   Publisher：日本心脈管作動物質学会  

    1型アンジオテンシンII(AT1受容体)に結合する新規因子(AT1 receptor-associated protein:ATRAP/Agtrap)の単離同定と構造解析、ATRAP/Agtrapの組織分布、ATRAP/AgtrapによるAT1受容体のinternalization促進作用、血管平滑筋細胞(VSMC)におけるATRAP/Agtrapの機能、生体におけるATRAP/Agtrapの発現調節の検討、血管壁を含む生体におけるATRAP/Agtrapの機能、ATRAP/Agtrapの発現・活性制御機構の検討について述べた。

    researchmap

  • メタボリック症候群モデルマウスに対する防風通聖散の多面的効果についての検討

    小豆島 健護, 田村 功一, 涌井 広道, 小林 竜, 畝田 一司, 大澤 正人, 金岡 知彦, 前田 晃延, 藤川 哲也, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   296 - 296   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ネフローゼ症候群を合併した片側腎動脈狭窄に対して血管内治療を行い、対側腎肥大の正常化と蛋白尿の消失を認めた一例

    涌井 広道, 小林 竜, 細川 由紀, 植田 瑛子, 鈴木 将太, 佐藤 陽, 吉田 伸一郎, 谷津 圭介, 橋本 達夫, 押川 仁, 田村 功一, 戸谷 義幸, 菅野 晃靖, 矢花 眞知子, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   396 - 396   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • アンジオテンシン受容体結合因子ATRAP/Agtrapの欠損は腎尿細管でのナトリウム再吸収を亢進させる

    大澤 正人, 田村 功一, 涌井 広道, 小豆島 健護, 畝田 一司, 小林 竜, 池谷 裕子, 前田 晃延, 金岡 知彦, 松田 みゆき, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   337 - 337   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 血性排液により発見された腹膜透析患者の非閉塞性腸管虚血症(NOMI)の一例

    小林 竜, 吉浦 辰徳, 柳 麻衣, 梅村 敏, 乾 雅人, 秀野 泰隆, 新海 宏, 小林 一博

    日本透析医学会雑誌   46 ( Suppl.1 )   967 - 967   2013.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 胸腔鏡下手術にてPD継続できた横隔膜交通症の2例

    吉浦 辰徳, 柳 麻衣, 小林 竜, 梅村 敏

    日本透析医学会雑誌   46 ( Suppl.1 )   944 - 944   2013.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 回腸導管造設術後に慢性腎不全の急性増悪及び代謝性アシドーシスをきたした1例

    小林 竜, 吉田 衝未, 志村 岳, 梅本 晋

    日本腎臓学会誌   54 ( 6 )   715 - 715   2012.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • ネフローゼ症候群の加療中に消化管穿孔をきたした1例

    小林 竜, 吉田 衝未, 志村 岳, 秀野 泰隆, 新海 宏, 小林 一博

    日本透析医学会雑誌   45 ( Suppl.1 )   705 - 705   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

▼display all

Awards

  • 優秀演題賞

    2024.3   第35回神奈川県CAPD研究会  

    　More details

  • Young Investigator Award

    2022.11   Japanese Society for Peritoneal Dialysis   Less sodium intake before PD start predicts good PD technique survival

    　More details

  • 横浜市立大学医学部 循環器・腎臓・高血圧内科学教室 同門会賞

    2017.12  

    小林 竜

    　More details

  • 日本高血圧学会YIA優秀賞

    2017.10   日本高血圧学会  

    小林 竜

    　More details

  • 日本腎臓学会YIA賞

    2017.8   日本腎臓学会  

    小林 竜

    　More details

  • 横浜市立大学大学院優秀論文賞

    2017.3   横浜市立大学  

    小林 竜

    　More details

  • 初期研修医奨励賞

    2010.2   日本消化器病学会関東支部  

    　More details

▼display all

Research Projects

  • AT1 receptor binding protein activation strategy in the treatment of hypertension and related organ injury

    Grant number：19K18010  2019.4 - 2021.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    KOBAYASHI Ryu

    　 More details

    Grant amount：\4160000 （ Direct Cost: \3200000 、 Indirect Cost：\960000 ）

    We have previously shown that ATRAP (angiotensin II receptor; associated protein; Agtrap) interacts with AT1R (angiotensin II type 1 receptor) and promotes constitutive internalization of AT1R so as to inhibit hyperactivation of its downstream signaling. ATRAP deficiency in proximal tubules did not exacerbate angiotensin-dependent hypertension in vivo. The results indicate that renal proximal tubule ATRAP has a minor role in angiotensin-dependent hypertension in vivo.

    researchmap

  • うつ病治療の新たなターゲットとしてのATRAPの可能性

    2018.7 - 2019.7

    一般財団法人横浜総合医学振興財団 

    小林 竜

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    researchmap

  • Therapeutic Strategy against Renal Aging via Novel Dual Actions of Receptor-binding Molecule

    Grant number：18H02735  2018.4 - 2022.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    TAMURA Kouichi

    　 More details

    Grant amount：\17160000 （ Direct Cost: \13200000 、 Indirect Cost：\3960000 ）

    Pathological activation of kidney AT1R signaling stimulates tubular sodium transporters, including epithelial sodium channels, to increase sodium reabsorption and blood pressure. During a search for a means to functionally and selectively modulate AT1R signaling, a molecule directly interacting with the carboxyl-terminal cytoplasmic domain of AT1R was identified and named AT1R-associated protein (ATRAP). We showed that ATRAP promotes constitutive AT1R internalization to inhibit pathological AT1R activation in response to certain stimuli. In the kidney, ATRAP is abundantly distributed in epithelial cells along the proximal and distal tubules. Results from genetically engineered mice with modified ATRAP expression show a pivotal role of ATRAP in pathological BP regulation and suggest that the function of kidney tubule ATRAP may be different between distal tubules and proximal tubules, implying that ATRAP is a target of interest in hypertension, aging, and several aging-related diseases.

    researchmap

  • 選択的受容体機能調節因子に着目した高血圧の新規治療戦略

    2017.4 - 2019.3

    日本学術振興会  研究活動スタート支援 

    小林 竜

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    researchmap